Skip to main content
Wellcome Open Research logoLink to Wellcome Open Research
. 2023 Nov 24;8:386. Originally published 2023 Sep 1. [Version 3] doi: 10.12688/wellcomeopenres.19774.3

Menstrual cycle features in mothers and daughters in the Avon Longitudinal Study of Parents and Children (ALSPAC)

Gemma Sawyer 1,2,a, Laura D Howe 1,2, Abigail Fraser 1,2, Gemma Clayton 1,2, Deborah A Lawlor 1,2, Gemma C Sharp 1,3
PMCID: PMC10665607  PMID: 37997583

Version Changes

Revised. Amendments from Version 2

The updated version of this manuscript addresses constructive comments from the second reviewer. The changes include specifying the age range of the mother (G0) and daughter (G1) samples across the data collection points in the Abstract and clarifying that the ages presented in Figures 1 and 2 reflect the average age of the relevant sample at each data collection point.

Abstract

Problematic menstrual cycle features, including irregular periods, severe pain, heavy bleeding, absence of periods, frequent or infrequent cycles, and premenstrual symptoms, are experienced by high proportions of females and can have substantial impacts on their health and well-being. However, research aimed at identifying causes and risk factors associated with such menstrual cycle features is sparse and limited. This data note describes prospective, longitudinal data collected in a UK birth cohort, the Avon Longitudinal Study of Parents and Children (ALSPAC), on menstrual cycle features, which can be utilised to address the research gaps in this area. Data were collected across 21 timepoints (between the average age of 28.6 and 57.7 years) in mothers (G0) and 20 timepoints (between the average age of 8 and 24 years) in index daughters (G1) between 1991 and 2020. This data note details all available variables, proposes methods to derive comparable variables across data collection timepoints, and discusses important limitations specific to each menstrual cycle feature. Also, the data note identifies broader issues for researchers to consider when utilising the menstrual cycle feature data, such as hormonal contraception, pregnancy, breastfeeding, and menopause, as well as missing data and misclassification.

Keywords: ALSPAC, menstruation, menstrual cycle, cohort, longitudinal

Introduction

Problematic menstrual cycle features have been reported to affect high proportions of adolescent girls, women, and people who menstruate. Previous research had indicated that 11–46% of females experience irregular periods 16 , 42–95% dysmenorrhea (menstrual pain) 14, 7 , 3–13% amenorrhea (absence of periods) 5, 8, 9 , 37–78% premenstrual syndrome (PMS) 1, 4 , 1–19% frequent or infrequent cycles (less than 24 or more than 38 days) 1, 8, 10 , and 4–58% heavy menstrual bleeding (HMB) 4, 8, 11 . Whilst most of these estimates come from research conducted in high income countries (HICs), the research conducted in low and middle income countries (LMICs) indicates similar prevalence ranges. However, the estimates do vary considerably, possible due to factors such as age, the setting and population under study, measurement and definition of the feature, and contextual attitudes towards menstruation. Such features may be related to other conditions, such as endometriosis, polycystic ovary syndrome (PCOS), or fibroids; however, many are idiopathic 10, 12, 13 . These relatively common problematic menstrual cycle features have been associated with several adverse physical and mental health outcomes, including infertility, anaemia, pain sensitivity, sleep disturbances, anxiety, and depression 7, 8, 14 . Research has also demonstrated a substantial impact on social wellbeing; negatively impacting school, work, relationships, exercise, and health-related quality of life 8, 15 .

Despite this, there has been relatively limited research to understand the causes and risk factors associated with problematic menstrual cycle features. Previous research has highlighted ethnicity 16 , family history 1, 2, 7, 12 , smoking 6, 12 , high or low BMI 2, 6, 7 , earlier age at menarche 2, 6, 7, 12 , presence of other menstrual problems 1, 7, 12 , and low socioeconomic position 1, 2, 6, 14, 16, 17 (SEP) as possible risk factors. However, much of the evidence comes from cross-sectional studies and research in clinical populations or university students. This means that many findings may be unrepresentative of broader populations, reports of menstrual cycle features may be hindered by recall bias, and there is a limited understanding of whether associations reflect causal effects or otherwise (e.g., confounding) and the direction of any causal effect. Further research is therefore necessary to understand the burden, life course risk factors, causes, and consequences of problematic menstrual cycle features, and provide insights into the causes and consequences of within and between woman variation in menstrual features. This would require greater use of prospective, longitudinal data on the menstrual cycle as well as factors that may be confounders, mediators, or moderators to enhance the accuracy of reporting and enable exploration of causal relationships.

Whilst there are limited resources that provide such rich menstrual cycle data, the Avon Longitudinal Study of Parents and Children (ALSPAC) is a longitudinal birth cohort with repeated measures data on features of the menstrual cycle across two generations of females, as well as data on a wide range of physical, psychological, social, and genetic factors. This data note aims to promote the use of the detailed menstrual cycle data available in ALSPAC to address these research needs. We describe the menstrual cycle data collected in the mothers (G0) and index daughters (G1) enrolled in ALSPAC, including repeated measures on menstrual cycle features throughout puberty and into early adulthood from questionnaire and clinic assessments.

Methods

ALSPAC

ALSPAC is a longitudinal birth cohort where pregnant women resident in Avon, UK with expected dates of delivery between 1 st April 1991 and 31 st December 1992 were invited to take part in the study. The initial number of pregnancies enrolled was 14,541, resulting in 13,988 children who were alive at 1 year of age.

When the oldest children were approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases who had failed to join the study originally. The total sample size for analyses using any data collected after the age of 7 is therefore 15,447 pregnancies and, of these, 14,901 children were alive at 1 year of age. There were 14,203 unique mothers initially enrolled in study but as a result of the additional phases of recruitment, 14,833 unique mothers enrolled in ALSPAC as of September 2021.

Study data gathered from participants at 22 years and onwards were collected and managed using Research Electronic Data Capture (REDCap) tools hosted at the University of Bristol 18 . REDCap is a secure, web-based software platform designed to support data capture for research studies.

Further details on ALSPAC have been published elsewhere 1921 . Please note that the study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool ( http://www.bristol.ac.uk/alspac/researchers/our-data/). Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (ALEC; IRB00003312). Detailed information can be found on the study website http://www.bristol.ac.uk/alspac/researchers/research-ethics/. Implicit consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

This data note focuses on two samples: G0 (mothers) and G1 (daughters) who have been asked about several menstrual cycle features at multiple timepoints. The G0 sample comprises mothers who were asked to report on their menstrual cycle features from the index pregnancy to menopause. Figure 1 shows the number of G0 participants responding to questions about periods at each relevant timepoint, and whether they had experienced a recent period. The female offspring (G1) sample comprises female participants who provided information, either reported by their mother or themselves, about menstrual cycle features from age 8 to age 24. Figure 2 shows the number of respondents who had started their period up until age 21.

Figure 1. Number of G0 participants (mothers) with recent periods.

Figure 1.

‘No recent period’ includes participants who reported no period in the last 12 months, no ‘recent’ periods, or no ‘periods nowadays’.

Figure 2. Number of G1 participants (daughters) who have started periods.

Figure 2.

‘Started period’ includes participants who responded yes when asked whether they had started their period yet or not at each timepoint.

Mothers (G0) Data

Participants answered questions relating to menstrual cycle length, absence of periods, regularity, heaviness, pain, and PMS-related symptoms across 17 questionnaires from the index pregnancy (reporting on menstruation prior to pregnancy) up to 28 years following birth of the index child (mean age 28.6 to 57.7 years). Participants also provided data on menstrual cycle features at four clinic assessments from mean age 47.4 to 52.6 years ( Table 1). Table 1 provides an overview of the ALSPAC questionnaires and clinics, participants mean age, and the relevant menstrual cycle feature variables at each timepoint, as well as contraception variables at each available timepoint.

Table 1. Source of G0 menstrual cycle and contraception data.

ALSPAC Source
File
Mean (SD) Age
G0 variable names
Cycle
length
Amenorrhea Cycle
regularity
Heavy/
prolonged
bleeding
Pain PMS Contraception
d Quest
28.6 (4.86)
years *
d012 d012 d011 - - -
f Quest
29.2 (4.78) years
- - - - - f036 f036a f068 f068a
g Quest
30.0 (4.74) years
- - - - - g036 g036a g054 g054a g133-g141
h Quest
32.0 (4.74) years
- - h112 h110 h113 h115a h111 h115b h028 h028a h044 h044a h098a-h098h h098j
j Quest
33.1 (4.69) years
- - j143 j141 j144 j142 j027 j027a j049 j049a j113-
j121
k Quest
34.0 (4.67) years
- - k1292 k1290 k1293
k1301
k1291 k1302 k1031 k1035 k1051 k1203-k1213
l Quest
35.1 (4.62) years
- - l3352 l3350 l3353 l3351 l3031 l3360
l3370 l3380
l3390 l3400
l3051 l3300-l3310
m Quest
36.1 (4.61) years
- - - m4201 m4202 - -
n Quest
37.8 (5.48) years
n1122 n1122 n1123 n1121 - - - n1130 n1133
p Quest
38.3 (4.60) years
- - p1262 p1260 p1263 p1261 p1031 p1270-
p1274 p1280-
p1284
p1061 p1243-
p1253
q Quest
39.3 (4.61) years
- - - - q4020 - q4280
r Quest
40.3 (4.63) years
r2082 r2082 r2083 r2081 - - - r2090 r2093 r2173-
r2183
s Quest
41.4 (4.55) years
- - s1262 s1260 s1263 s1261 s4020 s1031 s1270-
s1274 s1280-
s1284
s1243-s1253 s4280
FOM1 Clinic
47.4 (4.52) years
fm1ob120
fm1ob121
fm1ob126
fm1ob130 - - - fm1ob100
fm1ob101
t Quest
48.6 (4.49) years
- t4800 t4801
t4802 t4803
t4804 t4805
t4837 t4835 t4838 t4901 t4836 t4902 t4850-t4859 t4520-t4531 t5414
u Quest
49.7 (4.52) years
u1050 - u1050 - - - u1030-u1034
FOM2 Clinic
50.3 (4.42) years
fm2ob120
fm2ob121
fm2ob126
fm2ob130 - - - fm2ob100
fm2ob101
v Quest
51.3 (4.49) years
V4831 V4800 V4801
V4802 V4803
V4804 V4805
V4810
V4831 V4837 V4835 V4838
V4901
V4836 V4902 V4840 V4850-
V4859
V4550-V4565
FOM3 Clinic
51.6 (4.47) years
fm3ob120
fm3ob121
fm3ob126
fm3ob130 - - - fm3ob100 fm3ob101
FOM4 Clinic
52.6 (4.42) years
fm4ob120
fm4ob121
fm4ob126
fm4ob130 - - - fm4ob100
fm4ob101
Y Quest
57.7 (4.48) years
- Y5070 Y5080
Y5081 Y5082
Y5083 Y5084
Y5085 Y5100
- - - - Y5000-Y5014

*12 weeks’ gestation

Cycle length

In the first three questionnaires asking about cycle length (mean age 28.6, 37.8, and 40.3 years), participants were asked how many days there were from the start of one period to the start of the next one if their periods were regular. At the mean age 49.7 years questionnaire, participants were asked if their periods were regular and could select yes, alongside multiple options for the length of their cycle, or no. Similarly, at the aged 51.3 years questionnaire, participants were asked how many days there usually were between the start of one period and the start of the next and were provided with multiple categorical options, as well as an option to report that their periods were too irregular to estimate. These questions and variables are summarised in Table 2.

Table 2. Original and derived G0 cycle length variables (N (%)).

Question 28.6 years 37.8 years 40.3 years 49.7 years 51.3 years
Original variables
If regular, how many days were there from the start of one period to the start of the next one?
Mean (SD) 27.54 (3.85) 25.90 (6.36) 25.73 (6.57) - -
< 15 days * 107 (1.16) 419 (7.24) 388 (7.46) - -
15–20 days * 50 (0.54) 47 (0.81) 45 (0.87) - -
21–25 days * 1218 (13.15) 873 (15.08) 831 (15.98) - -
26–30 days * 7072 (76.35) 4103 (70.89) 3689 (70.96) - -
31–35 days * 747 (8.07) 322 (5.56) 226 (4.35) - -
36–40 days * 42 (0.45) 16 (0.28) 9 (0.17) - -
> 40 days * 26 (0.28) 8 (0.14) 11 (0.21) - -
Are your periods regular?
Yes, every 23 days or less - - - 283 (10.98) -
Yes, between 24 and 35 days - - - 1420 (55.10) -
Yes, more than every 35 days - - - 86 (3.34) -
No - - - 788 (30.58) -
In the years before your last period, how many days do you usually have between the start of one period and
the start of the next period?
Less than 21 days - - - - 329 (11.14)
21–25 days - - - - 594 (20.12)
26–31 days - - - - 1066 (36.11)
32–39 days - - - - 161 (5.45)
40–50 days - - - - 78 (2.64)
More than 50 days - - - - 96 (3.25)
Too irregular to estimate - - - - 628 (21.27)
Derived variables
Normal (24–38 days) 8246 (89.03) 4846 (83.72) 4331 (83.30) - -
Frequent (<24 days) 978 (10.56) 926 (16.00) 852 (16.39) - -
Infrequent (>38 days) 38 (0.41) 16 (0.28) 16 (0.31) - -

*Continuous responses recoded.

Amenorrhea

At the mean age 37.8- and 40.3-year questionnaires, participants who reported not having periods were asked whether this was because of pregnancy, hysterectomy, menopause, or another reason. At the aged 47.4 questionnaire, participants were asked whether they had a period in the last 12 months. Participants were also asked whether they had a period in the last 12 months at the mean aged 51.3 and 57.7 year questionnaires and all of the clinics, as well as additionally being asked whether they had a period in the last 3 months. Those who reported not having a period were subsequently asked to report the reason for this. Responses included surgery, ablation or resection, chemotherapy or radiation therapy, pregnancy or breastfeeding, menopause, various methods of contraception, and other reasons. Table 3 provides a summary of these questions and responses. Moreover, as mentioned above, participants were asked to report the number of days from the start of one period to the start of the next in three questionnaires (mean age 28.6, 37.8, and 40.3 years). These variables may also be informative regarding amenorrhea if participants have reported long cycle lengths (e.g., 84 days or 3 months between two periods).

Table 3. Original and derived G0 amenorrhea variables (N (%)).

Question 28.6
years
37.8
years
40.3
years
47.4
years
clinic
48.6
years
50.3
years
clinic
51.3
years
51.6
years
clinic
52.6
years
clinic
57.7
years
Original variables
If regular, how many days were there from the start of one period to the start of the next one?
Mean (SD) 27.54
(3.85)
25.90
(6.36)
25.73
(6.57)
- - - - - - -
< 15 days* 107 (1.16) 419
(7.24)
388
(7.46)
- - - - - - -
15–20 days* 50 (0.54) 47
(0.81)
45
(0.87)
- - - - - - -
21–25 days* 1218
(13.15)
873
(15.08)
831
(15.98)
- - - - - - -
26–30 days* 7072
(76.35)
4103
(70.89)
3689
(70.96)
- - - - - - -
31–35 days* 747 (8.07) 322
(5.56)
226
(4.35)
- - - - - - -
36–40 days* 42 (0.45) 16
(0.28)
9 (0.17) - - - - - - -
> 40 days* 26 (0.28) 8 (0.14) 11 (0.21) - - - - - - -
If you have no periods now, is this because of:
Pregnant - 92
(12.37)
49
(4.79)
- - - - - - -
Hysterectomy - 183
(24.60)
282
(27.54)
- - - - - - -
Menopausal - 79
(10.62)
213
(20.80)
- - - - - - -
Other reason - 363
(48.79)
467
(45.61)
- - - - - - -
Don’t know - 27
(3.63)
13
(1.27)
- - - - - - -
In the last 12 months, have you had a period or menstrual bleeding?
Yes - - - 3470
(69.15)
2669
(64.13)
1671
(56.26)
2206
(46.69)
1454
(46.57)
1175
(38.73)
571
(11.87)
No - - - 1548
(30.85)
1493
(35.87)
1299
(43.74)
2519
(53.31)
1668
(53.43)
1859
(61.27)
4239
(88.13)
In the last 3 months, have you had a period or menstrual bleeding?
Yes - - - 3149
(90.93)
- 1398
(64.48)
1855
(83.75)
1209
(49.57)
971
(82.64)
406
(71.86)
No - - - 314
(9.07)
- 770
(35.52)
360
(16.25)
1230
(50.43)
204
(17.36)
159
(28.14)
Reason why periods stopped
Hysterectomy - - - 339
(21.68)
- 199
(15.81)
- 219
(12.81)
233
(12.53)
-
Ablation or
resection
- - - 24
(1.53)
- - - - - -
Chemotherapy or
radiation therapy
- - - 38
(2.43)
- 32
(2.54)
- 43
(2.51)
36
(1.94)
-
Menopause - - - 763
(48.79)
- 751
(59.65)
- 1081
(63.22)
1237
(66.54)
-
Contraceptive:
hormonal coil
- - - 256
(16.37)
- - - 243
(14.21)
203
(10.92)
-
Contraceptive:
injection
- - - 62
(3.96)
- - - - - -
Contraceptive:
implant
- - - 5
(0.32)
- - - - - -
Contraceptive: pill - - - 59
(3.77)
- - - - - -
Contraceptive: other - - - 6
(0.38)
- - -
Other medical
reason
- - - 12
(0.77)
- 277
(22.00)
- 124
(7.25)
150
(8.07)
-
Were your periods stopped by:
Surgery - - - - 273
(20.15)
- - - - -
Chemotherapy or
radiation therapy
- - - - 48
(3.54)
- - - - -
Pregnancy or
breastfeeding
- - - - 6 (0.44) - - - - -
No obvious reason
/ menopause
- - - - 791
(58.38)
- - - - -
Other reason - - - - 237
(17.49)
- - - - -
Were your periods stopped by:
Surgery - - - - - - 325
(14.39)
- - -
Chemotherapy or
radiation therapy
- - - - - - 63
(2.79)
- - -
Pregnancy or
breastfeeding
- - - - - - - - -
No obvious reason
/ menopause
- - - - - - 1494
(66.16)
- - -
Contraception - - - - - - 372
(16.47)
- - -
Were your periods stopped by:
Surgery - - - - - - - - - 410
(10.30)
Chemotherapy or
radiation therapy
- - - - - - - - - 66
(1.66)
Pregnancy or
breastfeeding
- - - - - - - - - <5
Menopause - - - - - - - - - 3134
(78.76)
Contraception - - - - - - - - - 257
(6.46)
Other reason - - - - - - - - - 109
(2.74)
Derived variables
Period in last 3
months
9262 (NA) 5788
(NA)
5198
(NA)
3149
(62.84)
2669
(64.13)
1398
(47.93)
1855
(39.18)
1209
(39.01)
971
(32.00)
406
(8.45)
No period in last 3
months
<5 <5 <5 1862
(37.16)
1493
(35.87)
1519
(52.07)
2879
(60.82)
1890
(60.99)
2063
(68.00)
4398
(91.55)

Cell counts below 5 have been replaced with <5, and this may include 0.

Cycle regularity

Participants were asked whether their periods were regular or not in three of the questionnaires (mean age 28.6, 37.8, and 40.3 years) and were also asked whether their periods were very, moderately, mildly, or not at all irregular in eight of the questionnaires (mean age 32.0, 33.1, 34.0, 35.1, 38.3, 41.4, 48.6, and 51.3 years). In the four clinics (mean age 47.4, 50.3, 51.6, and 52.6 years) and mean age 49.7 years questionnaire, participants were asked about the regularity or length of their menstrual cycle and were able to report that their cycle was not regular or too irregular to estimate their cycle length. Table 4 gives an overview of these variables.

Table 4. Original and derived G0 cycle regularity variables (N (%)).

Question 28.6
years
32.0
years
33.1
years
34.0
years
35.1
years
37.8
years
38.3
years
40.3
years
41.4
years
47.4 years
clinic
48.6
years
49.7
years
50.3
years
clinic
51.3
years
51.6
years
clinic
52.6
years
clinic
Original variables
In the year before this pregnancy, would you say your periods were regular?
Yes 9880
(80.36)
- - - - - - - - - - - - - - -
No 2415
(19.64)
- - - - - - - - - - - - - - -
How would you describe your recent periods: Irregular?
Very - 737
(8.63)
732
(8.49)
- 665
(8.79)
- - - - - - - - - - -
Moderately - 670
(7.85)
708
(8.21)
- 721
(9.53)
- - - - - - - - - - -
Mildly - 1315
(15.40)
1404
(16.28)
- 1319
(17.43)
- - - - - - - - - - -
Not at all - 5815
(68.12)
5782
(67.03)
- 4862
(64.25)
- - - - - - - - - - -
Are your periods irregular?
Very - - - 931
(11.40)
- - 872
(12.09)
- 770
(12.87)
- 671
(22.28)
- - 1115
(26.20)
- -
Moderately - - - 778
(9.52)
- - 790
(10.95)
- 706
(11.80)
- 454
(15.07)
- - 857
(20.14)
- -
Mildly - - - 1376
(16.84)
- - 1254
(17.39)
- 1153
(19.27)
- 570
(18.92)
- - 823
(19.34)
- -
Not at all - - - 5084
(62.24)
- - 4297
(59.57)
- 3355
(56.07)
- 1317
(43.73)
- - 1461
(34.33)
- -
Would you say your periods are regular nowadays?
Yes - - - - - 6019
(83.31)
- 5393
(81.65)
- - - - - - - -
No - - - - - 1206
(16.69)
- 1212
(18.35)
- - - - - - - -
Periods are regular
Yes, every 28–30
days
- - - - - - - - - 1793
(51.78)
- - 626
(29.81)
- 489
(23.68)
352
(29.98)
Yes, < every 28
days
- - - - - - - - - 343
(9.90)
- - 198
(9.43)
- 140
(6.78)
102
(8.69)
Yes, > every 30
days
- - - - - - - - - 111
(3.21)
- - 68
(3.24)
- 70
(3.39)
32
(2.73)
No - - - - - - - - - 1216
(35.11)
- - 1208
(57.52)
- 1366
(66.15)
688
(58.60)
Are your periods regular?
Yes, every 23
days or less
- - - - - - - - - - - 283
(10.98)
- - - -
Yes, between 24
and 35 days
- - - - - - - - - - - 1420
(55.10)
- - - -
Yes, more than
every 35 days
- - - - - - - - - - - 86
(3.34)
- - - -
No - - - - - - - - - - - 788
(30.58)
- - - -
In the years before your last period, how many days do you usually have between the start of one period and the start of the next period?
Less than 21
days
- - - - - - - - - - - - - 329
(11.14)
- -
21–25 days - - - - - - - - - - - - - 594
(20.12)
- -
26–31 days - - - - - - - - - - - - - 1066
(36.11)
- -
32–39 days - - - - - - - - - - - - - 161
(5.45)
- -
40–50 days - - - - - - - - - - - - - 78
(2.64)
- -
More than 50
days
- - - - - - - - - - - - - 96
(3.25)
- -
Too irregular to
estimate
- - - - - - - - - - - - - 628
(21.27)
- -
Derived variables
Regular 9880
(80.36)
7130
(83.52)
7186
(83.31)
6460
(79.08)
6181
(81.68)
6019
(83.31)
5551
(76.96)
5393
(81.65)
4508
(75.33)
2247
(64.89)
1887
(62.65)
1789
(69.42)
892
(42.48)
2284
(53.67)
699
(33.85)
486
(41.40)
Irregular 2415
(19.64)
1407
(16.48)
1440
(16.69)
1709
(20.92)
1386
(18.32)
1206
(16.69)
1662
(23.04
1212
(18.35)
1476
(24.67)
1216
(35.11)
1125
(37.35)
788
(30.58)
1208
(57.52)
1972
(46.33)
1366
(66.15)
688
(58.60)

Heavy or prolonged bleeding

G0 participants were asked about heavy bleeding and prolonged bleeding separately. Participants were asked whether their periods were very, moderately, mildly, or not at all heavy in eight questionnaires (mean age 32.0, 33.1, 34.0, 35.1, 38.3, 41.4, 48.6, and 51.3 years). In addition, participants were asked whether they had had a dilation and curettage (D&C)/scrape due to heavy bleeding in five questionnaires (mean age 32.0, 34.0, 36.1, 48.6, and 51.3 years). In terms of prolonged bleeding, participants were asked to report the number of days that bleeding usually lasts for in eight questionnaires (mean age 32.0, 33.1, 34.0, 35.1, 38.3, 41.4, 48.6, and 51.3 years). These questions are summarised in Table 5.

Table 5. Original and derived G0 heavy and/or prolonged bleeding variables (N (%)).

Question 32.0 years 33.1 years 34.0 years 35.1 years 36.1 years 38.3 years 41.4 years 48.6 years 51.3 years
Original variables
How heavy are your periods?
Very 1321 (15.47) 1412 (16.35) 1408 (17.05) 1448 (18.48) - 1305 (17.95) 1127 (18.65) 765 (24.56) 1293 (29.81)
Moderately 4430 (51.89) 4522 (52.35) 4342 (52.59) 4049 (51.68) - 3712 (51.06) 2961 (48.99) 1293 (41.51) 1537 (35.44)
Mildly 2001 (23.44) 1884 (21.81) 1810 (21.92) 1775 (22.66) - 1583 (21.77) 1361 (22.52) 710 (22.79) 925 (21.33)
Not at all 785 (9.20) 820 (9.49) 696 (8.43) 562 (7.17) - 670 (9.22) 595 (9.84) 347 (11.14) 582 (13.42)
How many days does bleeding usually last?
Mean (SD) 5.26 (2.01) 5.26 (1.89) 5.23 (1.86) 5.22 (1.85) - 5.17 (1.85) 5.19 (2.14) 5.31 (2.35) 5.77 (3.14)
< 3 days * 129 (1.52) 157 (1.85) 165 (20.04) 143 (1.85) - 188 (2.72) 191 (3.33) 132 (4.36) 139 (3.34)
3 days 654 (7.72) 673 (7.95) 655 (8.12) 705 (9.13) - 65 (9.43) 564 (9.83) 318 (10.50) 370 (8.89)
4 days 1793 (21.16) 1732 (20.46) 1708 (21.16) 1601 (20.74) - 1455 (21.08) 1176 (20.50) 563 (18.59) 645 (15.50)
5 days 3188 (37.62) 3073 (36.30) 2900 (35.93) 2737 (35.46) - 2376 (34.42) 1979 (34.50) 962 (31.76) 1338 (32.16)
6 days 1276 (15.06) 1331 (15.72) 1227 (15.20) 1174 (15.21) - 976 (14.14) 796 (13.88) 402 (13.27) 560 (13.46)
7 days 997 (11.77) 1055 (12.46) 972 (12.04) 942 (12.20) - 909 (13.17) 698 (12.17) 433 (14.30) 661 (15.89)
8 days 179 (2.11) 182 (2.15) 181 (2.24) 181 (2.34) - 139 (2.01) 124 (2.16) 65 (2.15) 106 (2.55)
9 days 55 (0.65) 63 (0.74) 63 (0.78) 58 (0.75) - 51 (0.74) 41 (0.71) 28 (0.92) 48 (1.15)
< 9 days * 203 (2.40) 199 (2.35) 200 (2.48) 178 (2.31) - 158 (2.29) 167 (2.91) 126 (4.16) 294 (7.07)
Have you ever had a dilatation and curettage (D&C / scrape)? If yes, was this because of: heavy periods?
Yes 172 (1.84) - 62 (28.84) - 73 (52.52) - - 116 (77.33) 146 (74.11)
No 9179 (98.16) - 153 (71.16) - 66 (47.48) - - 34 (22.67) 51 (25.89)
Derived variables
Binary Heavy Bleeding **
Heavy 5751 (67.37) 5934 (68.70) 5750 (69.65) 5497 (70.17) - 5017 (69.01) 4088 (67.64) 2058 (66.07) 2830 (65.25)
Not heavy 2786 (32.63) 2704 (31.30) 2506 (30.35) 2337 (29.83) - 2253 (30.99) 1956 (32.36) 1057 (33.93) 1507 (34.75)
Binary Prolonged Bleeding
More than 8 days 258 (3.04) 262 (3.10) 263 (3.26) 236 (3.06) - 209 (3.03) 208 (3.63) 154 (5.08) 342 (8.22)
8 days or less 8216 (96.96) 8203 (96.90) 7808 (96.74) 7483 (96.94) - 6694 (96.97) 5528 (96.37) 2875 (94.92) 3819 (91.78)
Binary Heavy or Prolonged Bleeding
Heavy or prolonged bleeding 5780 (68.15) 5961 (69.67) 5781 (70.65) 5527 (71.03) - 5037 (70.42) 4117 (69.54) 2083 (67.65) 2868 (67.74)
Neither heavy nor prolonged bleeding 2701 (31.85) 2595 (30.33) 2402 (29.35) 2254 (28.97) - 2116 (29.58) 1803 (30.46) 996 (32.35) 1366 (32.26)

*Continuous responses recoded.

**Heavy bleeding is defined as reporting ‘very’ or ‘moderately’ heavy periods, whereas not heavy is defined as reporting periods that are ‘mildly’ or ‘not at all’ heavy.

Menstrual pain

Participants were asked whether their periods were very, moderately, mildly, or not at all painful in eight questionnaires (mean age 32.0, 33.1, 34.0, 35.1, 38.3, 41.4, 48.6, and 51.3 years) ( Table 6). Also, respondents were asked whether they had had a D&C/scrape due to painful periods in five questionnaires (mean age 32.0, 34.0, 36.1, 48.6, and 51.3 years) and whether they had used any medicines due to painful periods in two questionnaires (mean age 39.3 and 41.4 years).

Table 6. Original and derived G0 menstrual pain variables (N (%)).

Question 32.0 years 33.1 years 34.0 years 35.1 years 36.1 years 38.3 years 39.3 years 41.4 years 48.6 years 51.3 years
Original variables
How painful are your periods?
Very 526 (6.16) 592 (6.85) 581 (7.07) 610 (7.85) - 559 (7.73) - 459 (7.64) 263 (8.56) 466 (10.86)
Moderately 2063 (24.17) 2302 (26.65) 2217 (26.97) 2231 (28.73) - 2005 (27.72) - 1662 (27.66) 798 (25.97) 1084 (25.27)
Mildly 3388 (39.69) 3205 (37.11) 3256 (39.61) 3017 (38.85) - 2820 (38.99) - 2242 (37.32) 1127 (36.67) 1441 (33.59)
Not at all 2560 (29.99) 2538 (29.39) 2166 (26.35) 1908 (24.57) - 1848 (25.55) - 1645 (27.38) 885 (28.80) 1299 (30.28)
Have you ever had a dilatation and curettage (D&C / scrape)? If yes, was this because of: painful periods?
Yes 134 (1.43) - 48 (23.76) - 48 (40.00) - - - 52 (52.00) 60 (43.17)
No 9217 (98.57) - 154 (76.24) - 72 (60.00) - - - 48 (48.00) 79 (56.83)
Please indicate if you have used any medicines in the last 12 months: painful periods
Yes - - - - - - 2310 (28.37) 1909 (26.85) - -
No - - - - - - 5833 (71.63) 5200 (73.15) - -
Derived variables
Painful * 2589 (30.33) 2894 (33.51) 2798 (34.04) 2841 (36.58) - 2564 (35.45) - 2121 (35.30) 1061 (34.53) 1550 (36.13)
Not painful * 5948 (69.67) 5743 (66.49) 5422 (65.96) 4925 (63.42) - 4668 (64.55) - 3887 (64.70) 2012 (65.47) 2740 (63.87)

*Painful periods are defined as reporting ‘very’ or ‘moderately’ painful periods, whereas not painful is defined as reporting periods that are ‘mildly’ or ‘not at all’ painful.

Premenstrual symptoms

In eight questionnaires, participants were asked if they had any recent ‘problems with their period’ (mean age 29.2, 30.0, 32.0, 33.1, 34.0, 35.1, 38.3, and 41.1 years). Additionally, at the mean age 34.0 years questionnaire, participants were asked whether they had ‘pre-menstrual tension’ in the past year, and at the mean age 51.3 years questionnaire, participants were asked whether they had ‘particular problems’ in the days before or during their periods. Furthermore, in the latter five questionnaires (mean age 35.1, 38.3, 41.4, 48.6, and 51.3 years), those who reported having experienced problems with their periods were also asked which symptoms they experienced (very fatigued, irritable, depressed, anxious, or other) and whether each of these symptoms was experienced before their periods, during, or both. Table 7 summarises these questions and variables.

Table 7. Original and derived G0 premenstrual symptoms variables (N (%)).

Question 29.2 years 30.0 years 32.0 years 33.1 years 34.0 years 35.1 years 38.3 years 41.4 years 48.6 years 51.3 years
Original variables
Have you had any problems with your period since your baby was born / toddler was 8 months old / study child was 18 months old / child’s 5th birthday / child’s 6th birthday / child’s 10th birthday?
Yes, and saw a doctor 1135 (10.08) 1092 (10.65) 1148 (11.80) - - 1146 (13.39) 1357 (17.09) 984 (14.09) - -
Yes, and did not see a doctor 980 (8.70) 670 (6.54) 601 (6.18) - - 867 (10.13) 684 (8.62) 603 (8.63) - -
No 9150 (81.23) 8488 (82.81) 7976 (82.02) - - 6544 (76.48) 5898 (74.29) 5397 (77.28) - -
Have you had any problems with your period in the last year?
Yes, and saw a doctor - - - 1284 (13.39) - - - - - -
Yes, and did not see a doctor - - - 752 (7.84) - - - - - -
No - - - 7550 (78.76) - - - - - -
In the past year, have you had problems with your period?
Yes, and saw a doctor - - - - 1128 (12.61) - - - - -
Yes, and did not see a doctor - - - - 697 (7.79) - - - - -
No - - - - 7119 (79.60) - - - - -
In the past year, have you had pre-menstrual tension?
Yes, and saw a doctor - - - - 428 (4.79) - - - - -
Yes, and did not see a doctor - - - - 2970 (33.22) - - - - -
No - - - - 5542 (61.99) - - - - -
Do you generally find in the days before or during your periods you have particular problems?
Yes - - - - - - - - - 2241 (52.89)
No - - - - - - - - - 1996 (47.11)
Do you generally find in the days before or during your periods you have particular problems?
Very fatigued before - - - - - 3252 (37.78) 3016 (37.67) 2523 (35.73) 1264 (37.51) 1121 (26.18)
Very fatigued during - - - - - 2534 (29.47) 2266 (28.36) 1857 (26.35) 1049 (31.13) 768 (17.96)
Irritable before - - - - - 6350 (73.71) 5826 (72.56) 4683 (66.03) 2107 (62.52) 1744 (40.66)
Irritable during - - - - - 1954 (22.74) 1479 (18.51) 1142 (16.24) 601 (17.83) 419 (9.80)
Depressed before - - - - - 2682 (31.19) 2221 (27.79) 1598 (22.67) 864 (25.64) 759 (17.74)
Depressed during - - - - - 807 (9.40) 642 (8.05) 458 (6.52) 270 (8.01) 234 (5.47)
Anxious before - - - - - 2038 (23.71) 1662 (20.82) 1380 (19.59) 635 (18.84) 590 (13.79)
Anxious during - - - - - 564 (6.57) 461 (5.78) 356 (5.07) 193 (5.73) 200 (4.68)
Other before - - - - - 1149 (13.37) 970 (12.16) 954 (13.57) 371 (11.01) 369 (8.64)
Other during - - - - - 476 (5.54) 414 (5.19) 388 (5.53) 134 (3.98) 156 (3.65)
Derived variables
Binary variable: very fatigued *
Very fatigued - - - - - 4413 (51.26) 4114 (51.35) 3396 (48.03) 1662 (49.32) 1466 (34.18)
Not very fatigued - - - - - 4196 (48.74) 3898 (48.65) 3675 (51.97) 1708 (50.68) 2823 (65.82)
Binary variable: irritable *
Irritable - - - - - 6679 (77.53) 6098 (75.92) 4903 (69.12) 2183 (64.78) 1860 (43.34)
Not irritable - - - - - 1936 (22.47) 1934 (24.08) 2190 (30.88) 1187 (35.22) 2432 (56.66)
Binary variable: depressed *
Depressed - - - - - 2955 (34.37) 2454 (30.69) 1787 (25.34) 932 (27.66) 866 (20.22)
Not depressed - - - - - 5643 (65.63) 5541 (69.31) 5264 (74.66) 2438 (72.34) 3416 (79.78)
Binary variable: anxious *
Anxious - - - - - 2252 (26.20) 1859 (23.27) 1522 (21.60) 681 (20.21) 695 (16.24)
Not anxious - - - - - 6345 (73.80) 6129 (76.73) 5524 (78.40) 2689 (79.79) 3585 (83.76)
Binary variable: other symptoms *
Other symptoms - - - - - 1302 (15.15) 1120 (14.04) 1074 (15.28) 415 (12.31) 444 (10.39)
No other symptoms - - - - - 7292 (84.85) 6857 (85.96) 5957 (84.72) 2955 (87.69) 3830 (89.61)
Number of PMS-related symptoms
0 - - - - - 1502 (17.49) 1467 (18.40) 1689 (24.07) 806 (23.92) 2117 (49.59)
1 - - - - - 1794 (20.88) 1727 (21.67) 1504 (21.43) 767 (22.76) 548 (12.84)
2 - - - - - 2167 (25.23) 2134 (26.77) 1743 (24.84) 831 (24.66) 676 (15.84)
3 - - - - - 1448 (16.86) 1324 (16.61) 1055 (15.03) 507 (15.04) 444 (10.40)
4 - - - - - 1329 (15.47) 1066 (13.37) 810 (11.54) 372 (11.04) 393 (9.21)
5 - - - - - 350 (4.07) 253 (3.17) 217 (3.09) 87 (2.58) 91 (2.13)

*Participants are classified as experiencing the PMS-related symptom (very fatigued, irritable, depressed, anxious, or other) if they reported the symptom either before or during their period, whereas they are classified as not experiencing the symptom if they did not report the symptom before and during their period.

Daughters (G1) Data

Participants who had started their periods reported on menstrual regularity, heaviness, pain, cycle length, absence of periods, and PMS-related symptoms at multiple timepoints ranging from average 8 to 24 years. This included nine ‘puberty’ questionnaires, where mothers reported on their daughter’s menstrual cycle at age 8.1, 9.6, 10.6, 11.6, and 13.1 years before participants reported on their own menstrual cycle at age 14.6, 15.5, 16, and 17 years. Mothers also responded on behalf of their daughters at three ‘child-based’ questionnaires at age 13.1, 13.8, and 16.5 years. Participants answered further questions regarding their menstrual cycle features at two later ‘child-completed’ questionnaires (age 19.6 and 21 years) and six clinic assessments (age 11.7, 12.8, 13.8, 15.5, 17.8, and 24 years). Table 8 provides an overview of the relevant ALSPAC variables at each timepoint according to menstrual cycle features, as well as contraception variables at each available timepoint.

Table 8. Source of G1 menstrual cycle feature and contraception data.

ALSPAC Source File
Timepoint
G1 variable names
Cycle length Amenorrhea Cycle regularity Heavy/prolonged bleeding Dysmenorrhea/pain PMS Contraception
pub1 Puberty Quest
8.1 years
pub117 pub117 - pub115 pub116 pub120 pub122 pub123 - pub127
pub2 Puberty Quest
9.6 years
pub217 pub217 - pub215 pub216 pub220 pub222 pub223 - pub227
pub3 Puberty Quest
10.6 years
pub317 pub317 - pub315 pub316 pub320 pub321 pub322 pub323 - pub327
pub4 Puberty Quest
11.6 years
pub417 pub417 - pub415 pub416 pub420 pub421 pub422 pub423 - pub427
F11 Clinic
11.7 years
- - femn013 - - - -
tf1 Clinic
12.8 years
ff2094 ff2094 ff2093 - - - -
pub5 Puberty Quest
13.1 years
pub517 pub517 - pub515 pub516 pub520 pub521 pub522 pub523 - pub527
ta Child-Based Quest
13.1 years
- ta6190 ta6191 - - - - -
tb Child-Based Quest
13.8 years
- tb8390 tb8391 - - - - -
tf2 Clinic
13.8 years
- - fg6193 - - - -
pub6 Puberty Quest
14.6 years
pub617 pub617 - pub615 pub616 pub620 pub621 pub622 pub623 - pub627
pub7 Puberty Quest
15.5 years
pub717 pub717 - pub715 pub716 pub720 pub721 pub722 pub723 pub724 - pub727
pub8 Puberty Quest
16 years
pub817 pub817 - pub815 pub816 pub820 pub821 pub822 pub823 - pub827
tc Child-Based Quest
16.5 years
- tc5200 tc5201 - - - - -
pub9 Puberty Quest
17 years
pub917 pub917 - pub915 pub916 pub920 pub921 pub922 pub923 - pub927
tf4 Clinic
17.8 years
- - FJMS040 - - - FJMS010-FJMS014
ccxf Quest
19.6 years
ccxf3000 - ccxf3000 - - - ccxf2000-ccxf2004
YPA Quest
21 years
YPA7042 YPA7010 YPA7020-YPA7025 YPA7042 YPA7052 YPA7050 YPA7051 YPA7060-YPA7075 YPA3270-YPA3291
F24 Clinic
24 years
FKFH1020 FKFH1021 FKFH1020 FKFH1021 - - - FKFH1040

Cycle length

In the nine puberty questionnaires, as well as in the 12.8 year clinic, participants (or their mothers up to 13.1 years) were asked to report the length of their menstrual cycle. In two later questionnaires (19.6 and 21 years), participants were asked about their cycle length but were given multiple categorical options instead of reporting the exact number of days. At the age 24 clinic, participants were asked to provide the exact number of days of their usual menstrual cycle or, if they were unsure, they could select an approximate length from multiple categorical options. Table 9 provides an overview of these questions and variables.

Table 9. Original and derived G1 cycle length variables (N (%)).

Question 8.1 years 9.6 years 10.6 years 11.6 years 12.8 years clinic 13.1 years 14.6 years 15.5 years 16 years 17 years 19.6 years 21 years 24 years clinic
Original variables
In the past year, what was the usual length of your daughter’s menstrual cycle?
Mean (SD) NA 18 (18.84) 27.13 (14.86) 26.56 (11.29) - 26.20 (10.09) - - - - - - -
< 15 days * <5 <5 6 (15.00) 38 (12.54) - 140 (12.96) - - - - - - -
15–20 days * <5 <5 <5 8 (2.64) - 14 (1.30) - - - - - - -
21–25 days * <5 <5 6 (15.00) 40 (13.20) - 125 (11.57) - - - - - - -
26–30 days * <5 <5 17 (42.50) 175 (57.76) - 651 (60.28) - - - - - - -
31–35 days * <5 <5 7 (17.50) 22 (7.26) - 94 (8.70) - - - - - - -
36–40 days * <5 <5 <5 6 (1.98) - 15 (1.39) - - - - - - -
> 40 days * <5 <5 <5 14 (4.62) - 41 (3.80) - - - - - - -
If your periods are regular, how long on average would you say your cycle is? (i.e. number of days between each period e.g. 30, 28)
Mean (SD) - - - - 28.30 (2.40) - - - - - - - -
< 15 days * - - - - <5 - - - - - - - -
15–20 days * - - - - <5 - - - - - - - -
21–25 days * - - - - 44 (5.44) - - - - - - - -
26–30 days * - - - - 726 (89.74) - - - - - - - -
31–35 days * - - - - 29 (3.58) - - - - - - - -
36–40 days * - - - - <5 - - - - - - - -
> 40 days * - - - - <5 - - - - - - - -
In the past year, how many days were there usually between your periods?
Mean (SD) - - - - - - 28.35 (7.12) 27.81 (4.97) 27.62 (5.62) 27.32 (5.28) - - -
< 15 days * - - - - - - 13 (1.39) 12 (1.31) 11 (0.91) 11 (0.89) - - -
15–20 days * - - - - - - 18 (1.93) 12 (1.31) 37 (3.08) 14 (1.13) - - -
21–25 days * - - - - - - 138 (14.79) 168 (18.36) 229 (19.04) 311 (25.20) - - -
26–30 days * - - - - - - 636 (68.17) 610 (66.67) 791 (65.75) 773 (62.64) - - -
31–35 days * - - - - - - 92 (9.86) 89 (9.73) 109 (9.06) 98 (7.94) - - -
36–40 days * - - - - - - 12 (1.29) 12 (1.31) 14 (1.16) 16 (1.30) - - -
> 40 days * - - - - - - 24 (2.57) 12 (1.31) 12 (1.00) 11 (0.89) - - -
Are your periods regular?
Yes, every 23 days or less - - - - - - - - - - 423 (22.23) - -
Yes, between 24 and 35 days - - - - - - - - - - 973 (51.13) - -
Yes, > every 35 days - - - - - - - - - - 47 (2.47) - -
No - - - - - - - - - - 460 (24.17) - -
How many days do you usually have between the start of one period and the start of the next period?
Less than 21 days - - - - - - - - - - - 103 (5.03) -
21–25 days - - - - - - - - - - - 697 (34.07) -
26–31 days - - - - - - - - - - - 752 (36.75) -
32–39 days - - - - - - - - - - - 115 (5.62) -
40–50 days - - - - - - - - - - - 38 (1.86) -
More than 50 days - - - - - - - - - - - 40 (1.96) -
Too irregular to estimate - - - - - - - - - - - 301 (14.71) -
What is the length of your usual menstrual cycle (the interval from first day of period to first day of next period), when you are NOT using oral contraception, injections, or implant?
Mean (SD) - - - - - - - - - - - - 25.74 (9.47)
< 15 days * - - - - - - - - - - - - 122 (11.87)
15–20 days * - - - - - - - - - - - - 13 (1.26)
21–25 days * - - - - - - - - - - - - 154 (14.98)
26–30 days * - - - - - - - - - - - - 645 (62.74)
31–35 days * - - - - - - - - - - - - 69 (6.71)
36–40 days * - - - - - - - - - - - - 11 (1.07)
> 40 days * - - - - - - - - - - - - 14 (1.36)
If you don’t know exactly, would you say it was:
Less than 25 days - - - - - - - - - - - - 154 (12.10)
25–34 days - - - - - - - - - - - - 833 (65.44)
35–60 days - - - - - - - - - - - - 72 (5.66)
More than 60 days - - - - - - - - - - - - 15 (1.18)
Too irregular to estimate - - - - - - - - - - - - 199 (15.63)
Derived variables
Normal (24–38 days) <5 <5 26 (74.29) 221 (82.46) 776 (95.92) 806 (85.38) 788 (85.47) 762 (83.83) 981 (82.02) 975 (79.40) - - 782 (85.56)
Frequent (<24 days) <5 <5 6 (17.14) 31 (11.57) 28 (3.46) 87 (9.22) 104 (11.28) 128 (14.08) 197 (16.47) 232 (18.89) - - 112 (12.25)
Infrequent (>38 days) <5 <5 <5 16 (5.97) 5 (0.62) 51 (5.40) 30 (3.25) 19 (2.09) 18 (1.51) 21 (1.71) - - 20 (2.19)

Cell counts below 5 have been replaced with <5, and this may include 0.

*Continuous values recoded.

**Variables derived in line with clinical guidelines. 24–38 days is considered a normal cycle length, whereas less than 24 days is a frequent menstrual cycle and more than 38 days is an infrequent menstrual cycle.

Amenorrhea

In the 13.1, 13.8, and 16.5 year child-based questionnaires, mothers were asked whether there had been months when their daughter’s periods had not happened at all (if they had started regular periods) and subsequently, if yes, whether she had a period in the last three months. Similarly, at age 21, participants were asked if they had a period in the last three months and, if not, why their periods had stopped. Options included surgery, chemotherapy or radiation therapy, pregnancy or breastfeeding, no obvious reason or menopause, contraception, or that their periods had not started yet. Table 10 summarises these questions. Also, as discussed above, participants reported the length of their menstrual cycle in the nine puberty questionnaires and the 12.8 and 24 year clinic. These variables could provide further insight into amenorrhea where participants have reported long menstrual cycles (e.g., 84 days or 3 months between two periods).

Table 10. Original and derived G1 amenorrhea variables (N (%)).

Question 8.1 years 9.6 years 10.6 years 11.6 years 12.8 years clinic 13.1 years 13.1 years CBQ 13.8 years CBQ 14.6 years 15.5 years 16.0 years 16.5 years CBQ 17.0 years 21.0 years 24.0 years clinic
Original variables
In the past year, what was the usual length of your daughter’s menstrual cycle?
Mean (SD) NA 18 (18.84) 27.13 (14.86) 26.56 (11.29) - 26.20 (10.09) - - - - - - - - -
< 15 days * <5 <5 6 (15.00) 38 (12.54) - 140 (12.96) - - - - - - - - -
15–20 days * <5 <5 <5 8 (2.64) - 14 (1.30) - - - - - - - - -
21–25 days * <5 <5 6 (15.00) 40 (13.20) - 125 (11.57) - - - - - - - - -
26–30 days * <5 <5 17 (42.50) 175 (57.76) - 651 (60.28) - - - - - - - - -
31–35 days * <5 <5 7 (17.50) 22 (7.26) - 94 (8.70) - - - - - - - - -
36–40 days * <5 <5 <5 6 (1.98) - 15 (1.39) - - - - - - - - -
> 40 days * <5 <5 <5 14 (4.62) - 41 (3.80) - - - - - - - - -
If your periods are regular, how long on average would you say your cycle is? (i.e. number of days between each period e.g. 30, 28)
Mean (SD) - - - - 28.30 (2.40) - - - - - - - - - -
< 15 days * - - - - <5 - - - - - - - - - -
15–20 days * - - - - <5 - - - - - - - - - -
21–25 days * - - - - 44 (5.44) - - - - - - - - - -
26–30 days * - - - - 726 (89.74) - - - - - - - - - -
31–35 days * - - - - 29 (3.58) - - - - - - - - - -
36–40 days * - - - - <5 - - - - - - - - - -
> 40 days * - - - - <5 - - - - - - - - - -
If she (your daughter) has started her regular periods, have there been any months when the period didn’t happen at all?
Yes - - - - - - 487 (21.66) 605 (20.88) - - - 429 (14.92) - - -
No - - - - - - 1596 (71.00) 2107 (72.71) - - - 2185 (75.97) - - -
Don’t know - - - - - - 165 (7.34) 186 (6.42) - - - 262 (9.11) - - -
If yes, has she had any periods in the last 3 months?
Yes - - - - - - 503 (94.02) 580 (93.40) - - - 1569 (95.32) - - -
No - - - - - - 32 (5.98) 41 (6.60) - - - 77 (4.68) - - -
In the past year, how many days were there usually between your periods?
Mean (SD) - - - - - - - - 28.35 (7.12) 27.81 (4.97) 27.62 (5.62) - 27.32 (5.28) - -
< 15 days * - - - - - - - - 13 (1.39) 12 (1.31) 11 (0.91) - 11 (0.89) - -
15–20 days * - - - - - - - - 18 (1.93) 12 (1.31) 37 (3.08) - 14 (1.13) - -
21–25 days * - - - - - - - - 138 (14.79) 168 (18.36) 229 (19.04) - 311 (25.20) - -
26–30 days * - - - - - - - - 636 (68.17) 610 (66.67) 791 (65.75) - 773 (62.64) - -
31–35 days * - - - - - - - - 92 (9.86) 89 (9.73) 109 (9.06) - 98 (7.94) - -
36–40 days * - - - - - - - - 12 (1.29) 12 (1.31) 14 (1.16) - 16 (1.30) - -
> 40 days * - - - - - - - - 24 (2.57) 12 (1.31) 12 (1.00) - 11 (0.89) - -
In the last 3 months, have you had a period or menstrual bleeding?
Yes - - - - - - - - - - - - - 1784 (82.75) -
No - - - - - - - - - - - - - 372 (17.25) -
If no, were your periods stopped by:
Surgery - - - - - - - - - - - - - <5 -
Chemotherapy or radiation therapy - - - - - - - - - - - - - <5 -
Pregnancy or breastfeeding - - - - - - - - - - - - - 41 (12.85) -
No obvious reason / menopause - - - - - - - - - - - - - 10 (3.13) -
Contraception - - - - - - - - - - - - - 260 (81.50) -
Periods not started yet - - - - - - - - - - - - - 6 (1.88) -
What is the length of your usual menstrual cycle (the interval from first day of period to first day of next period), when you are NOT using oral contraception, injections, or implant?
Mean (SD) - - - - - - - - - - - - - - 25.74 (9.47)
< 15 days * - - - - - - - - - - - - - - 122 (11.87)
15–20 days * - - - - - - - - - - - - - - 13 (1.26)
21–25 days * - - - - - - - - - - - - - - 154 (14.98)
26–30 days * - - - - - - - - - - - - - - 645 (62.74)
31–35 days * - - - - - - - - - - - - - - 69 (6.71)
36–40 days * - - - - - - - - - - - - - - 11 (1.07)
> 40 days * - - - - - - - - - - - - - - 14 (1.36)
Derived variables
Period in last 3 months <5 6 (NA) 39 (NA) 300 (NA) 809 (NA) 1077 (NA) 503 (94.02) 580 (93.40) 930 (NA) 915 (NA) 1201 (NA) 1569 (95.32) 1233 (NA) 1784 (82.75) 1024 (NA)
No period in last 3 months <5 <5 <5 <5 <5 <5 32 (5.98) 41 (6.60) <5 <5 <5 77 (4.68) <5 372 (17.25) <5

CBQ: child-based questionnaire completed by mothers.

Cell counts below 5 have been replaced with <5, and this may include 0.

*Continuous responses recoded.

Cycle regularity

At the first three research clinics (11.7, 12.8, and 13.8 years), participants reported whether their periods were regular or not (or they didn’t know). At two later clinics (17.8 and 24 years) and two child-completed questionnaires (19.6 and 21 years), respondents were asked about the regularity or length of their cycle and, alongside a series of different cycle length options, were able to report that their cycle was not regular or too irregular for them to estimate their cycle length. In addition, in the mean age 21 questionnaire, participants were asked whether their periods were very, moderately, mildly, or not at all irregular. Table 11 provides an overview of these variables and summarises the responses of those who had started their periods.

Table 11. Original and derived G1 cycle regularity variables (N (%)).

Question 11.7 years clinic 12.8 years clinic 13.8 years clinic 17.8 years clinic 19.6 years 21 years 24 years clinic
Original variables
(Teenagers’) periods are regular
Yes 274 (51.99) 817 (49.13) 1309 (61.03) - - - -
No 155 (29.41) 504 (30.31) 560 (26.11) - - - -
Don’t know 98 (18.60) 342 (20.57) 276 (12.87) - - - -
Periods are regular
Yes, occur every 28–30 days - - - 1843 (66.80) - - -
Yes, occur less than every 28 days - - - 220 (7.97) - - -
Yes, occur more than every 30 days - - - 132 (4.78) - - -
No - - - 564 (20.44) - - -
Are your periods regular?
Yes, every 23 days or less - - - - 423 (22.23) - -
Yes, between 24 and 35 days - - - - 973 (51.13) - -
Yes, > every 35 days - - - - 47 (2.47) - -
No - - - - 460 (24.17) - -
Are/were your periods irregular?
Very - - - - - 326 (15.62) -
Moderately - - - - - 300 (14.37) -
Mildly - - - - - 443 (21.23) -
Not at all - - - - - 1018 (48.78) -
How many days do you usually have between the start of one period and the start of the next period?
Less than 21 days - - - - - 103 (5.03) -
21–25 days - - - - - 697 (34.07) -
26–31 days - - - - - 752 (36.75) -
32–39 days - - - - - 115 (5.62) -
40–50 days - - - - - 38 (1.86) -
More than 50 days - - - - - 40 (1.96) -
Too irregular to estimate - - - - - 301 (14.71) -
Approximate length of usual menstrual cycle
Less than 25 days - - - - - - 154 (12.10)
25–34 days - - - - - - 833 (65.44)
35–60 days - - - - - - 72 (5.66)
More than 60 days - - - - - - 15 (1.18)
Too irregular to estimate - - - - - - 199 (15.63)
Derived variables
Regular 274 (63.87) 817 (61.85) 1309 (70.04) 2195 (79.56) 1443 (75.83) 1448 (68.37) 1074 (84.37)
Irregular 155 (36.13) 504 (38.15) 560 (29.96) 564 (20.44) 460 (24.17) 670 (31.63) 199 (15.63)

Heavy or prolonged bleeding

In the nine puberty questionnaires, participants (or their mothers up to 13.1 years) were asked whether they had experienced heavy or prolonged bleeding with their period. Following this, participants who reported heavy or prolonged bleeding were asked whether they had contacted a doctor for this. Participants were also asked to report the number of days bleeding they normally experienced. If participants were unsure about the exact number of days, they could instead select one of three options: 3 days or less, 4–6 days, or 7 days or more. In the age 21 questionnaire, participants were asked whether their periods were very, moderately, mildly, or not at all heavy. Table 12 provides a summary of these variables and the responses amongst G1 participants who had started their periods.

Table 12. Original and derived G1 heavy and/or prolonged bleeding variables (N (%)).

Question 8.1 years 9.6 years 10.6 years 11.6 years 13.1 years 14.6 years 15.5 years 16 years 17 years 21 years
Original variables
Has your daughter ever had any of the following symptoms associated with their period: heavy or prolonged bleeding?
Yes <5 <5 9 (12.33) 99 (18.97) 421 (21.92) - - - - -
No <5 13 (NA) 64 (87.67) 423 (81.03) 1500 (78.08) - - - - -
Have you had any of the following symptoms associated with your period: heavy or prolonged bleeding?
Yes - - - - - 908 (34.15) 850 (34.34) 1007 (36.53) 920 (35.91) -
No - - - - - 1751 (65.85) 1625 (65.66) 1750 (63.47) 1642 (64.09) -
If yes, did you contact a doctor for this?
Yes <5 <5 <5 22 (22.45) 56 (13.37) 128 (14.17) 145 (17.26) 268 (26.61) 289 (31.58) -
No <5 <5 6 (NA) 76 (77.55) 363 (86.63) 775 (85.83) 695 (82.74) 739 (73.39) 626 (68.42) -
In the past year, how many days of bleeding has your daughter usually had during each period?
Mean (SD) 2 (NA) 2.50 (1.78) 4.48 (1.93) 5.22 (1.66) 5.41 (1.44) - - - - -
< 3 days * <5 9 (75.00) 12 (19.05) 17 (3.97) 21 (1.37) - - - - -
3 days <5 <5 6 (9.52) 42 (9.81) 80 (5.24) - - - - -
4 days <5 <5 11 (17.46) 60 (14.02) 252 (16.49) - - - - -
5 days <5 <5 16 (25.40) 139 (32.48) 510 (33.38) - - - - -
6 days <5 <5 9 (14.29) 71 (16.59) 332 (21.73) - - - - -
7 days <5 <5 7 (11.11) 87 (20.33) 273 (17.87) - - - - -
8 days <5 <5 <5 6 (1.40) 39 (2.55) - - - - -
9 days <5 <5 <5 <5 8 (0.52) - - - - -
> 9 days * <5 <5 <5 5 (1.17) 13 (0.85) - - - - -
In the past year, how many days of bleeding have you usually had during each period?
Mean (SD) - - - - - 5.54 (2.15) 5.38 (1.33) 5.39 (1.32) 5.31 (1.94) -
< 3 days * - - - - - 6 (0.36) 11 (0.69) 15 (0.78) 21 (1.11) -
3 days - - - - - 72 (4.29) 74 (4.62) 90 (4.66) 107 (5.68) -
4 days - - - - - 264 (15.74) 277 (17.29) 318 (16.48) 359 (19.05) -
5 days - - - - - 602 (35.90) 579 (36.14) 715 (37.05) 700 (37.14) -
6 days - - - - - 365 (21.77) 344 (21.47) 384 (19.90) 339 (17.98) -
7 days - - - - - 300 (17.89) 262 (16.35) 347 (17.98) 296 (15.70) -
8 days - - - - - 44 (2.62) 39 (2.43) 37 (1.92) 39 (2.07) -
9 days - - - - - 7 (0.42) 7 (0.44) 11 (0.57) 8 (0.42) -
> 9 days * - - - - - 17 (1.01) 9 (0.56) 13 (0.67) 16 (0.85) -
If you don’t know, is it probably:
7 days or more <5 <5 <5 15 (11.72) 46 (9.89) 141 (11.52) 122 (11.52) 118 (11.71) 104 (12.46) -
4–6 days <5 <5 6 (50.00) 86 (67.19) 352 (75.70) 1016 (83.01) 884 (83.47) 826 (81.94) 656 (78.56) -
3 days or less <5 <5 6 (50.00) 27 (21.09) 67 (14.41) 67 (5.47) 53 (5.00) 64 (6.35) 75 (8.98) -
How heavy were/are your periods?
Very - - - - - - - - - 312 (14.89)
Moderately - - - - - - - - - 1060 (50.57)
Mildly - - - - - - - - - 581 (27.72)
Not at all - - - - - - - - - 143 (6.82)
Derived variables
Heavy or prolonged bleeding ** <5 <5 10 (13.51) 100 (18.87) 429 (22.14) 919 (34.04) 852 (34.18) 1012 (36.44) 923 (35.90) 1372 (65.46)
Neither heavy nor prolonged bleeding ** <5 13 (NA) 64 (86.49) 430 (81.13) 1509 (77.86) 1781 (65.96) 1641 (65.82) 1765 (63.56) 1648 (64.10) 724 (34.54)

Cell counts below 5 have been replaced with <5, and this may include 0.

*Continuous responses recoded.

**Heavy bleeding is defined as reporting ‘heavy or prolonged bleeding’, more than 8 days bleeding, or ‘very’/‘moderately’ heavy periods, whereas not heavy is defined as reporting ‘no heavy or prolonged bleeding’, bleeding for 8 days or less, or periods that are ‘mildly’/’not at all’ heavy.

Menstrual pain

In the puberty questionnaires, except for 15.5 years, participants (or their mothers up to 13.1 years) were asked whether or not they had experienced severe cramps with their periods. At age 15.5, they were instead asked whether they had experienced pain with their periods, and then, for those who answered yes, whether the pain was severe, moderate, or mild. All puberty questionnaires also asked participants who reported severe cramps or pain with their periods whether they had contacted a doctor for this. In the age 21 questionnaire, participants were asked whether their periods were very, moderately, mildly, or not at all painful. Table 13 provides a summary of these variables.

Table 13. Original and derived G1 menstrual pain variables (N (%)).

Question 8.1 years 9.6 years 10.6 years 11.6 years 13.1 years 14.6 years 15.5 years 16 years 17 years 21 years
Original variables
Has your daughter ever had any of the following symptoms associated with her period: severe cramps?
Yes <5 5 (33.33) 10 (15.87) 126 (26.30) 563 (32.13) - - - - -
No <5 10 (66.67) 53 (84.13) 353 (73.70) 1189 (67.87) - - - - -
Have you ever had any of the following symptoms associated with your period: severe cramps?
Yes - - - - - 1271 (48.85) - 1515 (56.32) 1451 (57.92) -
No - - - - - 1331 (51.15) - 1175 (43.68) 1054 (42.08) -
Have you ever had any of the following symptoms associated with your period: pain with your period?
Yes - - - - - - 2108 (85.10) - - -
No - - - - - - 369 (14.90) - - -
If so, were they mild, moderate, or severe?
Severe - - - - - - 405 (19.33) - - -
Moderate - - - - - - 1114 (53.17) - - -
Mild - - - - - - 576 (27.49) - - -
If yes, did you contact a doctor for this?
Yes <5 <5 <5 14 (11.20) 49 (8.81) 148 (11.75) 194 (9.29) 327 (21.61) 371 (25.76) -
No <5 <5 6 (NA) 111 (88.80) 507 (91.19) 1112 (88.25) 1894 (90.71) 1186 (78.39) 1069 (74.24) -
How painful are/were your periods?
Very - - - - - - - - - 327 (15.60)
Moderately - - - - - - - - - 686 (32.73)
Mildly - - - - - - - - - 785 (37.45)
Not at all - - - - - - - - - 298 (14.22)
Derived variables
Painful * <5 <5 10 (15.87) 126 (26.30) 563 (32.13) 1271 (48.85) 1519 (61.65) 1515 (56.32) 1451 (57.92) 1013 (48.33)
Not painful * <5 10 (NA) 53 (84.13) 353 (73.70) 1189 (67.87) 1331 (51.15) 945 (38.35) 1175 (43.68) 1054 (42.08) 1083 (51.67)

Cell counts below 5 have been replaced with <5, and this may include 0.

*Painful periods are defined as reporting ‘severe cramps’, ‘severe/moderate pain with your period’, or ‘very/moderately’ painful periods, whereas not painful is defined as reporting ‘no severe cramps’, ‘mild/no pain with your period’, or periods that are ‘mildly/not at all’ painful.

Premenstrual symptoms

At 21 years only ( Table 14), participants were asked whether they experienced ‘particular problems’ in the days before or during their periods. Those who responded yes were subsequently asked which problems they experienced and were provided with multiple symptoms: very fatigued, irritable, depressed, anxious, or other. Respondents indicated whether they experienced each of these symptoms before their periods, during their periods, or not at all (participants were able to select more than one option).

Table 14. Original and derived G1 premenstrual symptoms variables (N (%)).

Question 21 years
Original variables
Do/did you generally find that in the days before or during your
periods you have particular problems?
Yes 1101 (52.23)
No 1007 (47.77)
If yes, which problems do you experience: very fatigued?
Yes, before 438 (20.48)
Yes, during 460 (21.50)
No, I don’t experience this 425 (19.87)
If yes, which problems do you experience: irritable?
Yes, before 790 (36.90)
Yes, during 523 (24.44)
No, I don’t experience this 124 (5.80)
If yes, which problems do you experience: depressed?
Yes, before 466 (21.80)
Yes, during 324 (15.15)
No, I don’t experience this 482 (22.53)
If yes, which problems do you experience: anxious?
Yes, before 274 (12.82)
Yes, during 188 (8.79)
No, I don’t experience this 723 (33.80)
If yes, which problems do you experience: other?
Yes, before 288 (13.47)
Yes, during 154 (7.20)
No, I don’t experience this 374 (17.48)
Derived variables
Binary variable: very fatigued *
Very fatigued 668 (32.19)
Not very fatigued 1407 (67.81)
Binary variable: irritable *
Irritable 986 (47.04)
Not irritable 1110 (52.96)
Binary variable: depressed *
Depressed 613 (29.56)
Not depressed 1461 (70.44)
Binary variable: anxious *
Anxious 365 (17.66)
Not anxious 1702 (82.34)
Binary variable: other symptoms *
Other symptoms 288 (17.45)
No other symptoms 1362 (82.55)
Number of PMS-related symptoms
0 998 (61.38)
1 138 (8.49)
2 189 (11.62)
3 161 (9.90)
4 92 (5.66)
5 48 (2.95)

*Participants are classified as experiencing the PMS-related symptom (very fatigued, irritable, depressed, anxious, or other) if they reported the symptom either before or during their period, whereas they are classified as not experiencing the symptom if they did not report the symptom before and during their period.

Using the menstrual cycle feature data

Whilst few of the menstrual cycle feature variables are consistent across all available timepoints, it is possible to derive comparable variables for most features and timepoints. However, there are some important limitations that need to be considered when deriving such variables and planning analyses.

Cycle length

For both G0 and G1, participants reported the exact number of days of their menstrual cycle at multiple timepoints and this data could be used continuously or could be used to create categorical variables. For the continuous data, it is important to be aware of outliers in the data, with a small number of G0 participants reporting cycle lengths as long as 90 days and G1 participants reporting cycle lengths up to 150 days. It is challenging to know whether these responses reflect genuine long cycle lengths, for example reflecting an episode of amenorrhea, or if they are due to data entry errors or participants misunderstanding these questions. Approaches to managing these potential erroneous outliers will depend on the research questions being addressed and could include keeping all participants in the analyses and then repeating analyses with those whose cycle lengths are notably different to most participants (e.g. 4 standard deviations away from the mean), or some other threshold to see if the outlying values influence results, and reclassifying some participants at each reporting timepoint as having amenorrhea if they report a cycle length of 84 days or more (cessation of menstruation for three months). A further issue, however, is that of small peaks in the distribution around 5 days at some of the timepoints ( Figure 3), suggesting that some individuals are reporting the number of days bleeding rather than cycle length. This needs to be managed when deriving variables for analyses. One possible method is to use multiple imputation to impute responses less than a certain threshold (e.g., 10), with responses to the same question at other timepoints contributing to the imputation model. Similar to managing outliers, there will be multiple methods that could be adopted to handle these possible misinterpretations, and a sensitivity analysis to compare results with different approaches is advised. Moreover, the wording of the questions varied at different timepoints for the G1 sample, which may have impacted how participants responded. For example, some questions specified that the length of a usual menstrual cycle referred to the interval from the first day of period to the first day of next period whereas others did not provide this clarification. It is possible therefore that some participants may have reported the number of days between the end of the first period and the start of the next period at some timepoints, possibly impacting the accuracy of reporting and how appropriate it is to compare responses between timepoints. Researchers should consider how to manage this limitation when designing their analyses.

Figure 3. Histograms showing G0 and G1 cycle length variables.

Figure 3.

3A is from the G0 37.8 year questionnaire and 3B is from the G0 40.3 year questionnaire. 3C is from the G1 13.1 year puberty questionnaire and 3D is from the G1 age 24 clinic assessment.

Researchers may want to derive categorical variables to describe infrequent, frequent, and normal cycles ( Table 2 and Table 9). Normal cycles are considered to range from 24–38 days, whereas cycles shorter than 24 days are considered frequent and those longer than 38 days are considered infrequent 10 . Such variables could be derived from the continuous variables (noting the issues above). Unfortunately, although ALSPAC also collected categorical data at some timepoints, the original variable categories do not always align with the clinical definitions of infrequent/frequent/normal. Moreover, the boundaries vary between the data collection timepoints. At some G0 and G1 timepoints, the categories are 23 days or less, 24–35 days, and more than every 35 days, whereas at others, the categories are less than 21 days, 21–25 days, 26–31 days, 32–39 days, 40–50 days, and more than 50 days. Finally, at the age 24 timepoint for G1, the categories are less than 25 days, 25–34 days, 35–60 days, and more than 60 days. Therefore, it may not be plausible to include all the available timepoints in the desired analyses, depending on its nature and the timepoints of interest.

Amenorrhea

Binary variables can be derived for amenorrhea for both G0 and G1 (no period in at least the last 3 months vs. had a period in the last 3 months) at each timepoint ( Table 3 and Table 10). However, most respondents who reported not having a period in the last 3 months provided a reason (e.g., surgery, chemotherapy, pregnancy, menopause, contraception, or not started their periods yet). It is also possible that this may be the case at timepoints where participants were not asked to provide a reason. Information on contraception use and other possible explanations is available from other data collection waves but not necessarily from same wave in which information on amenorrhea was collected (see further considerations below). This could be utilised to attempt to infer whether a participant who has reported not having a period in the last 3 months was also on contraception that could have explained this.

The cycle length variables whereby participants reported the exact number of days of their cycles could also be utilised. To be consistent with the above variables, the cycle length variables could be used to derive binary variables reflecting cycles of 84 days or more (i.e., no period in the last 3 months) compared with cycles of less than 84 days. This would be consistent with clinical guidelines which characterise amenorrhea, specifically secondary amenorrhea, as the cessation of menstruation for three months 13, 22 . However, as discussed above, it is possible that the high values reported by participants in response to questions about their cycle length could be the result of data entry errors and therefore researchers should be cautious including these variables.

Cycle regularity

For both G0 and G1, the cycle regularity data could be used to derive a binary variable at each timepoint (regular vs. irregular) whereby a participant is classified as having irregular periods if they reported that their period was not regular, too irregular to estimate their cycle length, or very/moderately irregular ( Table 4 and Table 11). Alternatively, the more granular 4-level variables for G0 (very, moderately, mildly, or not at all irregular) could be maintained as they are available at half of the timepoints (mean age 32.0 33.1, 34.0, 35.1, 38.3, 41.4, 48.6, and 51.3 years) if these are the only timepoints being considered in the analysis.

Heavy or prolonged bleeding

For the G0 sample, granular 4-level heavy bleeding variables (very, moderately, mildly, or not at all) could be utilised as these are available at each timepoint or binary variables could be derived (very or moderately heavy vs. mildly or not at all heavy). Also, at each of these timepoints, participants reported the duration of bleeding. Binary variables for prolonged bleeding, which is defined as more than 8 days bleeding 10 , could therefore also be derived (>8 days bleeding vs. 8 days bleeding or less) ( Table 5).

For G1 however, it is not possible to separate heavy and prolonged bleeding in line with clinical guidelines due to the questions that were asked 10 . Instead, binary variables for heavy or prolonged bleeding could be derived (heavy or prolonged bleeding vs. neither heavy nor prolonged bleeding), whereby those who reported heavy or prolonged bleeding, very or moderately heavy bleeding, or bleeding for more than 8 days are classified as having heavy or prolonged bleeding ( Table 12). Unfortunately, the G1 categorical response variables for days bleeding (3 days or less, 4–6 days, or 7 days or more) do not reflect the clinical guidelines regarding prolonged bleeding so are more challenging to incorporate into this binary definition. It would also be possible to derive the same binary variables for the G0 sample if it was more appropriate for the specific research question to have comparable variables across the two generations ( Table 5).

A key consideration with regards to the number of days bleeding variables is that there are some outliers. For example, at the G0 mean age 41.4 year questionnaire and the aged 14.6 and 17 G1 puberty questionnaire, participants reported up to 60 days bleeding. These outliers could be due to data entry errors, participants misunderstanding the question as relating to intervals between periods, or they could be genuine responses reflecting very long periods of bleeding. It is not possible with the available data to distinguish the reasons for such high values and therefore there is no clear way to handle such outliers. Approaches could include recoding such values (e.g., 4 SDs from the mean or the 99th percentile) as missing, imputing them based on available data at other timepoints, or replacing them with the highest non-outlier value (‘top-coding’). The most appropriate method will depend on the nature of the analyses being conducted; however, it may be beneficial to conduct a sensitivity analysis to compare the results with different approaches to handling the outliers.

Menstrual pain

It is possible to derive binary pain variables for both G0 and G1 ( Table 6 and Table 13). Most of the G1 pain-related variables are already in a binary format except for the age 15 and 21 ones. These variables could be dichotomised whereby those reporting severe or moderate pain are categorised as having pain associated with their periods. The G0 variables could be dichotomised whereby those reporting very/moderately painful periods could be categorised as having pain associated with their periods, or these could be utilised as 4-level variables if appropriate for the analysis to maintain granularity.

However, some caution is needed regarding the G1 variables as the differences in the wording of the questions may mean that participants responded differently to the binary puberty questions. The majority of the puberty questions ask about ‘severe cramps’ whereas the 15.5 puberty question asks about ‘pain with your period’ and, subsequently, whether these are severe, moderate, or mild. These are slightly different concepts, and this does appear to be reflected in the responses as the preceding and following timepoint have 48.9% and 56.3% of people reporting severe cramps respectively, but only 16.4% of all respondents at 15.5 report severe pain and 61.7% report severe or moderate pain.

Premenstrual symptoms

There are multiple ways in which the PMS-related variables could be used depending on the nature of analysis. Firstly, a binary variable could be derived which reflects experiencing ‘particular problems’, ‘problems with their period’, ‘pre-menstrual tension’, or any of the listed problems related to periods (irritable, anxious, depressed, very fatigued, other) vs no problems. Secondly, binary variables could be derived for each of these symptoms separately (e.g., irritable vs not irritable). These variables could be derived separately or together for before and during the period. This would be useful for examining the timing of specific symptoms and for distinguishing symptoms occurring during a period from those occurring before, in line with clinical definitions of PMS 23, 24 . Finally, it would also be possible to derive a variable reflecting the number of PMS-related symptoms an individual experiences, either before their periods only (in line with clinical definitions of PMS) or during a period ( Table 7 and Table 14). Whilst PMS is not defined by a specific number of symptoms, this variable, which would range from 0 (no PMS symptoms) to 5 (all listed PMS symptoms), could be useful to examine the severity of PMS as more symptoms may reflect a greater negative impact on daily functioning 23, 24 .

A key consideration for the PMS-related data is that PMS encompasses a wide range of physical and psychological symptoms. There are additional common PMS-related symptoms, such as headaches, acne, and breast tenderness 23, 24 , which are not reported in the ALSPAC data. Whilst there is an option for participants to report other problems with their period, we cannot be sure how participants have interpreted this, nor that people have reported all other relevant symptoms. A further issue with the G0 data is that some of the earlier timepoints only ask about ‘particular problems’ but are not followed up with questions about which symptoms are experienced and their timing. A broad range of problems could be labelled by participants as ‘particular problems’, not all of which would necessarily be considered PMS. Therefore, there may be some misclassification. Misclassification may also arise due to the retrospective nature of such assessments, which have been suggested to result in an overreporting of symptoms compared with prospective diary reporting 25 . Finally, the G1 data is somewhat limited because it is only available at one timepoint.

Further considerations

Contraception is a primary factor that must be considered when utilising the menstrual cycle feature data outlined above. Hormonal contraception is particularly prevalent and, although participants on hormonal contraception will not experience natural menstrual cycles, some will experience withdrawal bleeds that they may classify as menstrual periods (and respond to questions about their menstrual cycle features accordingly). In addition, hormonal contraception is often prescribed in response to menstrual cycle issues such as heavy menstrual bleeding, irregular cycles, or pain. Therefore, as menstrual cycle features and contraception are bidirectionally associated, it may be inappropriate to adjust for or exclude those on hormonal contraception depending on the analyses being conducted. For example, research examining whether BMI influences heavy menstrual bleeding would not want to exclude individuals on hormonal contraception as BMI can impact the likelihood of using hormonal contraception. Excluding would therefore result in collider bias and potentially result in a spurious association between BMI and heavy menstrual bleeding. There are other methods that may account for hormonal contraception when conducting analyses such as this, possibly including multiple imputation, meta-regression, and probability weighting, and there is data available on contraception in ALSPAC to enable this. Table 15 and Table 16 provide a summary of the available contraceptive variables for G0 and G1 respectively.

Table 15. G0 contraception variables (N (%)).

Question 29.2 years 30.0 years 32.0 years 33.1 years 34.0 years 35.1 years 37.8 years 38.3 years 39.3 years 40.3 years 41.4 years 47.4 years clinic 48.6 years 49.7 years 50.3 years clinic 51.3 years 51.6 years clinic 52.6 years clinic 57.7 years
Since the baby was born / toddler was 8 months old / child was 18 months old / in the past year / child’s 5 th birthday / in the last 2 years, how often have you used the following: contraceptive pill?
Every day 4625 (40.99) 3414 (33.03 2655 (27.55) 2447 (25.60) 2066 (2.98) 1765 (20.63) - 1229 (15.47) - - - - 262 (6.63) - - - - - -
Often 450 (3.99) 611 (5.91) 727 (7.54) 416 (4.35) 296 (3.29) 271 (3.17) - 190 (2.39) - - - - 32 (0.81) - - - - - -
Sometimes 677 (6.00) 726 (7.02) 795 (8.25) 478 (5.00) 344 (3.83) 276 (3.23) - 213 (2.68) - - - - 36 (0.91) - - - - - -
Not at all 5530 (49.02) 5585 (54.03) 5460 (56.66) 6216 (65.04) 6286 (69.91) 6243 (72.97) - 6313 (79.46) - - - - 3624 (91.65) - - - - - -
What forms of contraception are you using now?
Withdrawal - 204 (2.35) 248 (2.60) 237 (2.80) - - - - - - - - - - - - - - -
The pill - 3409 (39.31) 2964 (31.13) 2635 (31.08) - - - - - - - - - - - - - - -
IUCD / coil - 750 (8.65) 757 (7.95) 831 (9.80) - - - - - - - - - - - - - - -
Condom / sheath - 1861 (21.47) 1767 (18.56) 1863 (21.97) - - - - - - - - - - - - - - -
Calendar / rhythm method - 138 (1.59) 137 (1.44) 183 (2.16) - - - - - - - - - - - - - - -
Diaphragm / cap - 149 (1.72) 108 (1.13) 101 (1.19) - - - - - - - - - - - - - - -
Spermicide - 158 (1.82) 156 (1.64) 131 (1.55) - - - - - - - - - - - - - - -
None - 1272 (14.67) 2272 (23.86) 885 (10.44) - - - - - - - - - - - - - - -
Other - 728 (8.40) 1113 (11.69) 1612 (19.01) - - - - - - - - - - - - - - -
What forms of contraception are you using now?
Withdrawal - - - - 225 (2.86) 231 (2.96) - 207 (2.78) - 177 (2.50) 190 (2.90) - 84 (2.57) - - - - - -
The pill - - - - 2221 (26.49) 1953 (25.01) - 1247 (16.72) - 932 (13.14) 809 (12.36) - 252 (7.70) - - - - - -
IUCD / coil - - - - 858 (10.23) 856 (10.96) - 848 (11.37) - 873 (12.31) 824 (12.59) - 551 (16.83) - - - - - -
Condom / sheath - - - - 1640 (19.56) 1480 (18.95) - 1126 (15.10) - 968 (13.65) 821 (12.55) - 330 (10.08) - - - - - -
Calendar / rhythm method - - - - 178 (2.12) 242 (3.10) - 101 (1.35) - 91 (1.28) 78 (1.19) - 40 (1.22) - - - - - -
Diaphragm / cap - - - - 85 (1.01) 41 (0.53) - 43 (0.58) - 32 (0.45) 36 (0.55) - 8 (0.24) - - - - - -
Spermicide - - - - 100 (1.19) 137 (1.75) - 54 (0.72) - 34 (0.48) 37 (0.57) - 15 (0.46) - - - - - -
I have been sterilised / am no longer fertile - - - - 676 (8.06) 737 (9.44) - 983 (13.18) - 985 (13.89) 1025 (15.67) - 421 (12.86) - - - - - -
My partner has been sterilised - - - - 1221 (14.57) 1383 (17.71) - 1942 (26.05) - 2060 (29.05) 1949 (29.79) - 1047 (31.99) - - - - - -
None - - - - 816 (9.73) 434 (5.56) - 660 (8.85) - 613 (8.64) 575 (8.79) - 399 (12.19) - - - - - -
Other - - - - 363 (4.33) 315 (4.03) - 245 (3.29) - 327 (4.61) 199 (3.04) - 126 (3.85) - - - - - -
Have you ever used the contraceptive pill?
Yes - - - - - - 7410 (94.85) - - 7169 (94.12) - - - - - - - - -
No - - - - - - 402 (5.15) - - 448 (5.88) - - - - - - - - -
Are you on the pill now?
Yes - - - - - - 1402 (18.59) - - 999 (13.91) - - - - - - - - -
No - - - - - - 6138 (81.41) - - 6184 (86.09) - - - - - - - - -
Have you used any medicines in the last 12 months for: oral contraceptive?
Yes - - - - - - - - 1184 (14.54) - 788 (11.08) - - - - - - - -
No - - - - - - - - 6969 (85.46) - 6321 (88.92) - - - - - - - -
Are you currently taking oral contraceptives?
Yes - - - - - - - - - - - 336 (6.69) - - 149 (4.98) 120 (3.83) - - 101 (3.33)
No - - - - - - - - - - - 4686 (93.31) - - 2841 (95.02) 3011 (96.17) - - 2933 (96.67)
Are you currently using contraceptive injection?
Yes - - - - - - - - - - - 42 (0.84) - - 39 (1.31) 31 (0.99) - - 25 (0.82)
No - - - - - - - - - - - 4980 (99.16) - - 2936 (98.69) 3100 (99.01) - - 3009 (99.18)
Are you currently using:
Oral contraceptive pill - - - - - - - - - - - - - 268 (27.10) - - - - -
Contraceptive injection - - - - - - - - - - - - - 36 (3.64) - - - - -
Contraceptive implant - - - - - - - - - - - - - 27 (2.73) - - - - -
Contraceptive coil with hormone - - - - - - - - - - - - - 653 (66.03) - - - - -
Contraceptive patch - - - - - - - - - - - - - 5 (0.51) - - - - -
What forms of contraception are you and your partner using now? (please cross all that you have used in the past 3 months)
Withdrawal - - - - - - - - - - - - - - - 78 (1.81) - - 38 (0.80)
The pill - - - - - - - - - - - - - - - 201 (4.68) - - 56 (1.19)
IUD (coil, no hormones) - - - - - - - - - - - - - - - 111 (2.58) - - 41 (0.87)
IUD (coil, with hormones, such as a mirena coil) - - - - - - - - - - - - - - - 527 (12.26) - - 310 (6.56)
Condom / sheath - - - - - - - - - - - - - - - 250 (5.82) - - 89 (1.88)
Calendar / rhythm method 21 (0.49) <5
Diaphragm / cap - - - - - - - - - - - - - - - <5 - - <5
Spermicide - - - - - - - - - - - - - - - 11 (0.26) - - <5
Contraceptive injection - - - - - - - - - - - - - - - 29 (0.67) - - 11 (0.23)
Contraceptive implant - - - - - - - - - - - - - - - 31 (0.72) - - 11 (0.23)
I have been sterilised - - - - - - - - - - - - - - - 335 (7.79) - - 189 (4.00)
My partner has been sterilised - - - - - - - - - - - - - - - 781 (18.17) - - 277 (5.86)
I am no longer fertile - - - - - - - - - - - - - - - 853 (19.84) - - 2156 (45.65)
None - - - - - - - - - - - - - - - 734 (17.07) - - 1371 (29.03)
Other - - - - - - - - - - - - - - - 333 (7.75) - - 174 (3.68)

Table 16. G1 contraception variables (N (%)).

Question 8.1 years 9.6 years 10.6 years 11.6 years 13.1 years 14.6 years 15.5 years 16 years 17 years 17.8 years clinic 19.6 years 21 years 24 years clinic
Has your daughter taken oral contraceptives or birth control pills for any reason during the past 12 months?
Yes <5 <5 <5 5 (0.96) 22 (1.13) - - - - - - - -
No <5 15 (NA) 75 (NA) 518 (99.04) 1927 (98.87) - - - - - - - -
Have you taken oral contraceptives or birth control pills for any reason during the past 12 months?
Yes - - - - - 176 (6.55) 327 (13.16) 695 (25.20) 1110 (43.38) - - - -
No - - - - - 2490 (92.70) 2139 (86.11) 2044 (74.11) 1435 (56.08) - - - -
Don’t know - - - - - 18 (0.72) 18 (0.72) 19 (0.69) 14 (0.55) - - - -
Currently taking contraception / Are you currently using
Oral contraceptive
pill
- - - - - - - - - 1069 (73.83) 1015 (52.97) - -
Contraceptive injection - - - - - - - - - 115 (7.94) 74 (3.86) - -
Contraceptive implant - - - - - - - - - 33 (2.28) 136 (7.10) - -
Contraceptive coil with hormone - - - - - - - - - 7 (0.48) 25 (1.30) - -
Contraceptive patch - - - - - - - - - <5 5 (0.26) - -
None - - - - - - - - - 221 (15.26) 661 (34.50 - -
Which method of contraception (if any) are you or your sexual partner currently using? Cross true or false for each option
I do not currently have a sexual partner - - - - - - - - - - - 392 (11.88) -
Not using any contraception - - - - - - - - - - - 443 (13.42) -
I / My partner has been sterilised - - - - - - - - - - - <5 -
Mini pill - - - - - - - - - - - 150 (4.55) -
Combined pill - - - - - - - - - - - 519 (15.73) -
Pill – not sure which - - - - - - - - - - - 759 (23.00) -
Mirena coil - - - - - - - - - - - 72 (2.18) -
Coil / other device - - - - - - - - - - - 55 (1.67) -
Condom - - - - - - - - - - - 354 (10.73) -
Femidom - - - - - - - - - - - <5 -
Cap / diaphragm - - - - - - - - - - - <5 -
Foams / gels / sprays / pessaries - - - - - - - - - - - <5 -
Contraceptive sponge - - - - - - - - - - - <5 -
Persona - - - - - - - - - - - <5 -
Safe period / rhythm method - - - - - - - - - - - 5 (0.15) -
Withdrawal - - - - - - - - - - - 80 (2.42) -
Injection - - - - - - - - - - - 91 (2.76) -
Implant - - - - - - - - - - - 273 (8.27) -
Emergency contraception - - - - - - - - - - - 49 (1.48) -
Going without sex - - - - - - - - - - - 42 (1.27) -
Don’t know / not sure - - - - - - - - - - - <5 -
Another method of contraception - - - - - - - - - - - 5 (0.15) -
Method of contraception used
Combined pill - - - - - - - - - - - - 867 (36.72)
Progesterone only pill - - - - - - - - - - - - 200 (8.47)
Contraceptive injection - - - - - - - - - - - - 91 (3.85)
Contraceptive implant - - - - - - - - - - - - 282 (11.94)
Contraceptive patch - - - - - - - - - - - - 8 (0.34)
Coil - - - - - - - - - - - - 95 (4.02)
Hormonal coil / vaginal ring - - - - - - - - - - - - 111 (4.70)
Barrier methods - - - - - - - - - - - - 149 (6.31)
Natural family planning - - - - - - - - - - - - 27 (1.14)
None - - - - - - - - - - - - 531 (22.49)

ALSPAC has collected data on multiple other reproductive factors that can influence menstrual cycle features, and researchers should consider these when planning analyses. Pregnancies and breastfeeding will result in absences of menstruation and can result in more problematic periods upon their initial resumption. Also, menopause and surgeries such as hysterectomies and oophorectomies will stop menstruation and therefore researchers will need to consider how to account for this. Age at menarche is another important factor assessed in ALSPAC which some researchers may want to consider depending on their research question. Whilst ALSPAC participants have been asked about recent pregnancies, breastfeeding, menopause, surgeries and hormonal contraceptive use, the questions are not necessarily asked at the same timepoint as the menstrual cycle features and therefore including such variables may require making inferences backwards or forwards in time.

Moreover, many of the menstrual cycle questions ask participants about their most recent period. Whilst most participants are likely to be answering such questions regarding a period they had up to one month ago, others may be answering about periods much further back in time prior to going on hormonal contraception, becoming pregnant, having a hysterectomy or oophorectomy or going through menopause. This further highlights the importance of considering other reproductive factors where possible to ensure only participants who are experiencing a menstrual cycle at the time of reporting are included in analyses. This is also important to consider as recall bias may become an issue for those who are answering questions about menstrual cycles that were experienced many months or years ago.

There is some limited data available on health conditions that might cause the problematic menstrual cycle features summarised in this data note. For example, participants were asked whether they had ever been diagnosed with PCOS at age 22 for G1 and mean age 49.7 for G0. The same question was asked about endometriosis at age 22 for G1 only. These data provide an opportunity to identify individuals whose problematic menstrual cycle features at previous timepoints are a result of one of these underlying disorders. However, as these conditions tend to be both underdiagnosed and take a long time to be diagnosed, the data is unlikely to capture all participants whose menstrual cycle features are due to either PCOS or endometriosis. There are many other factors which ALSPAC has detailed data on and, depending on the research question, researchers may wish to consider alongside menstrual features.

Missing data needs to be considered when using menstrual symptom data in ALSPAC. Missing data, for example due to loss to follow up, or participants not responding to some questions, could lead to selection bias if missingness is related to the exposure and outcome being explored 26 . Missing menstrual symptom data could be due to a variety of reasons, including withdrawing from ALSPAC, loss to follow-up, not wanting to answer some questions, pregnancy, breastfeeding, menopause, contraception, and surgeries. It is plausible that several of these (e.g., withdrawal, loss to follow-up, pregnancy, breastfeeding) are socially patterned and hence likely to relate to the exposures and outcomes that are being related to the menstrual cycle features and therefore selection bias is possible. How this is explored and dealt with will depend on the specific research question being addressed and the pattern and extent of missing data. There are several papers that can help with exploring this, including ones that have been used previously in ALSPAC studies 27, 28 .

One of the primary benefits of the ALSPAC dataset is the repeated measures of menstrual cycle features at multiple timepoints. This may allow researchers to increase their sample size by maintaining participants who have missing data at one timepoint by combining with data from other similar timepoints with multiple imputation. Beyond this, repeated measures can enable trajectory modelling to explore the causes and consequences of different patterns of menstrual cycle features over time if appropriate for the research question. The longitudinal nature of the data enables it to be utilised to assess causal relationships between menstrual cycle features and possible causes and consequences, reducing the likelihood of reverse causality.

However, researchers should also consider the possibility of misclassification. Whilst random measurement error is always a possibility, researchers should consider possible sources of systematic measurement error. For example, particular groups may feel more uncomfortable answering questions regarding their menstrual cycle and therefore provide answers that do not reflect their menstrual cycle features, or certain groups may be more or less likely to notice or report their menstrual cycle features. The subjective nature of many of the questions may also contribute to possible misclassification as participants may have different perspectives as to what constitutes certain symptoms, such as “heavy bleeding” or “severe cramps”. However, subjective experience of these features is crucial and is considered in the clinical guidelines for diagnosis of HMB 10 . Moreover, menstrual cycle features may vary randomly over time, contributing to random error and the possibility of regression dilution when using repeated measures 29 . Researchers therefore need to be aware of both random and systematic measurement error and address this as much as possible within their analysis.

Acknowledgements

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

Funding Statement

This work was supported by the UK Medical Research Council, Wellcome [217065, <a href=https://doi.org/10.35802/217065>https://doi.org/10.35802/217065</a>] and the University of Bristol who provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). This publication is the work of the authors and they will serve as guarantors for the contents of this paper. Gemma Sawyer is supported by a Wellcome Trust PhD studentship in Molecular, Genetic and Lifecourse Epidemiology [218495, <a href=https://doi.org/10.35802/218495>https://doi.org/10.35802/218495</a>].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[version 3; peer review: 2 approved]

Data availability

Underlying data

ALSPAC data access is through a system of managed open access. The steps below highlight how to apply for access to the data included in this data note and all other ALSPAC data. The datasets presented in this article are linked to ALSPAC project number B4175; please quote this project number during your application. The ALSPAC variable codes highlighted in the dataset descriptions can be used to specify required variables.

  • 1. Please read the ALSPAC access policy which describes the process of accessing the data and samples in detail, and outlines the costs associated with doing so.

  • 2. You may also find it useful to browse our fully searchable research proposal database which lists all research projects that have been approved since April 2011.

  • 3. Please submit your research proposal for consideration by the ALSPAC Executive Committee. You will receive a response within 10 working days to advise you whether your proposal has been approved.

If you have any questions about accessing data, please email alspac-data@bristol.ac.uk. The study website also contains details of all the data that is available through a fully searchable data dictionary.

References

  • 1. Shiferaw MT, Wubshet M, Tegabu D: Menstrual problems and associated factors among students of Bahir Dar University, Amhara National Regional State, Ethiopia: A cross-sectional survey. Pan Afr Med J. 2014;17: 246. 10.11604/pamj.2014.17.246.2230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Hu Z, Tang L, Chen L, et al. : Prevalence and Risk Factors Associated with Primary Dysmenorrhea among Chinese Female University Students: A Cross-sectional Study. J Pediatr Adolesc Gynecol. 2020;33(1):15–22. 10.1016/j.jpag.2019.09.004 [DOI] [PubMed] [Google Scholar]
  • 3. Armour M, Ferfolja T, Curry C, et al. : The Prevalence and Educational Impact of Pelvic and Menstrual Pain in Australia: A National Online Survey of 4202 Young Women Aged 13-25 Years. J Pediatr Adolesc Gynecol. 2020;33(5):511–518. 10.1016/j.jpag.2020.06.007 [DOI] [PubMed] [Google Scholar]
  • 4. Parker MA, Sneddon AE, Arbon P: The menstrual disorder of teenagers (MDOT) study: Determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers. BJOG. 2010;117(2):185–92. 10.1111/j.1471-0528.2009.02407.x [DOI] [PubMed] [Google Scholar]
  • 5. Wiksten-Almströmer M, Hirschberg AL, Hagenfeldt K: Prospective follow-up of menstrual disorders in adolescence and prognostic factors. Acta Obstet Gynecol Scand. 2008;87(11):1162–8. 10.1080/00016340802478166 [DOI] [PubMed] [Google Scholar]
  • 6. Kwak Y, Kim Y, Baek KA: Prevalence of irregular menstruation according to socioeconomic status: A population-based nationwide cross-sectional study. PLoS One. 2019;14(3): e0214071. 10.1371/journal.pone.0214071 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Iacovides S, Avidon I, Baker FC: What we know about primary dysmenorrhea today: A critical review. Hum Reprod Update. 2015;21(6):762–78. 10.1093/humupd/dmv039 [DOI] [PubMed] [Google Scholar]
  • 8. Harlow S, Campbell OM: Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG. 2004;111(1):6–16. 10.1111/j.1471-0528.2004.00012.x [DOI] [PubMed] [Google Scholar]
  • 9. Nur Azurah AG, Sanci L, Moore E, et al. : The Quality of Life of Adolescents with Menstrual Problems. J Pediatr Adolesc Gynecol. 2013;26(2):102–8. 10.1016/j.jpag.2012.11.004 [DOI] [PubMed] [Google Scholar]
  • 10. Munro MG, Critchley HOD, Fraser IS, et al. : The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. 10.1002/ijgo.12666 [DOI] [PubMed] [Google Scholar]
  • 11. Bitzer J, Serrani L: Women’s attitudes towards heavy menstrual bleeding, and their impact on quality of life. Open Access J Contracept. 2013;4:21–28. 10.2147/OAJC.S38993 [DOI] [Google Scholar]
  • 12. Gutman G, Nunez AT, Fisher M: Dysmenorrhea in adolescents. Curr Probl Pediatr Adolesc Health Care. 2022;52(5): 101186. 10.1016/j.cppeds.2022.101186 [DOI] [PubMed] [Google Scholar]
  • 13. Klein DA, Paradise SL, Reeder RM: Amenorrhea: A systematic approach to diagnosis and management. Am Fam Physician. 2019;100(1):39–48. [PubMed] [Google Scholar]
  • 14. Gagua T, Tkeshelashvili B, Gagua D, et al. : Assessment of anxiety and depression in adolescents with primary dysmenorrhea: A case-control study. J Pediatr Adolesc Gynecol. 2013;26(6):350–4. 10.1016/j.jpag.2013.06.018 [DOI] [PubMed] [Google Scholar]
  • 15. Karlsson TS, Marions LB, Edlund MG: Heavy menstrual bleeding significantly affects quality of life. Acta Obstet Gynecol Scand. 2014;93(1):52–7. 10.1111/aogs.12292 [DOI] [PubMed] [Google Scholar]
  • 16. Kiran A, Geary RS, Gurol-Urganci I, et al. : Sociodemographic differences in symptom severity and duration among women referred to secondary care for menorrhagia in England and Wales: A cohort study from the National Heavy Menstrual Bleeding Audit. BMJ Open. 2018;8(2): e018444. 10.1136/bmjopen-2017-018444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Jacobs MB, Boynton-Jarrett RD, Harville EW: Adverse childhood event experiences, fertility difficulties and menstrual cycle characteristics. J Psychosom Obstet Gynaecol. 2015;36(2):46–57. 10.3109/0167482X.2015.1026892 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Harris PA, Taylor R, Thielke R, et al. : Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. 10.1016/j.jbi.2008.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Boyd A, Golding J, Macleod J, et al. : Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42(1):111–27. 10.1093/ije/dys064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Fraser A, Macdonald-Wallis C, Tilling K, et al. : Cohort profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013;42(1):97–110. 10.1093/ije/dys066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Northstone K, Lewcock M, Groom A, et al. : The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019 [version 1; peer review: 2 approved]. Wellcome Open Res. 2019;4:51. 10.12688/wellcomeopenres.15132.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Practice Committee of the American Society for Reproductive Medicine: Current evaluation of amenorrhea. Fertil Steril. 2004;82 Suppl 1:S33–9. 10.1016/j.fertnstert.2004.07.001 [DOI] [PubMed] [Google Scholar]
  • 23. Hofmeister S, Bodden S: Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Am Fam Physician. 2016;94(3):236–40. [PubMed] [Google Scholar]
  • 24. Itriyeva K: Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Curr Probl Pediatr Adolesc Health Care. 2022;52(5): 101187. 10.1016/j.cppeds.2022.101187 [DOI] [PubMed] [Google Scholar]
  • 25. Knaapen L, Weisz G: The biomedical standardization of premenstrual syndrome. Stud Hist Philos Biol Biomed Sci. 2008;39(1):120–34. 10.1016/j.shpsc.2007.12.009 [DOI] [PubMed] [Google Scholar]
  • 26. Lee KJ, Tilling KM, Cornish RP, et al. : Framework for the treatment and reporting of missing data in observational studies: The Treatment And Reporting of Missing data in Observational Studies framework. J Clin Epidemiol. 2021;134:79–88. 10.1016/j.jclinepi.2021.01.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Howe LD, Tilling K, Galobardes B, et al. : Loss to follow-up in cohort studies: Bias in estimates of socioeconomic inequalities. Epidemiology. 2013;24(1):1–9. 10.1097/EDE.0b013e31827623b1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Hughes RA, Heron J, Sterne JAC, et al. : Accounting for missing data in statistical analyses: Multiple imputation is not always the answer. Int J Epidemiol. 2019;48(4):1294–304. 10.1093/ije/dyz032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Rutter CE, Millard LAC, Borges MC, et al. : Exploring regression dilution bias using repeat measurements of 2858 variables in up to 49 000 UK Biobank participants. medRxiv. 2022. 10.1101/2022.07.13.22277605 [DOI] [PMC free article] [PubMed] [Google Scholar]
Wellcome Open Res. 2023 Nov 27. doi: 10.21956/wellcomeopenres.22766.r70508

Reviewer response for version 3

Mandikudza Tembo 1

Approved

Are sufficient details of methods and materials provided to allow replication by others?

Partly

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Reviewer Expertise:

Menstrual health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Wellcome Open Res. 2023 Nov 22. doi: 10.21956/wellcomeopenres.22386.r68897

Reviewer response for version 2

Jenny Doust 1

Thank you for responding to the comments that I made. This is a useful piece of work summarising the data available in the ALSPAC data set

Are sufficient details of methods and materials provided to allow replication by others?

Yes

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Reviewer Expertise:

Women's health  Epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Wellcome Open Res. 2023 Oct 25. doi: 10.21956/wellcomeopenres.22386.r68896

Reviewer response for version 2

Mandikudza Tembo 1

Thank you for the changes made. I have no further comments to make.

Are sufficient details of methods and materials provided to allow replication by others?

Partly

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Reviewer Expertise:

Menstrual health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Wellcome Open Res. 2023 Oct 10. doi: 10.21956/wellcomeopenres.21901.r67570

Reviewer response for version 1

Jenny Doust 1

This paper outlines the data recorded on menstrual cycle features for mothers and index daughters in the Avon Longitudinal Study of Parents and Children. The multi-generational and longitudinal nature of the data makes it valuable to researchers.

The data note helpfully outlines what data has been collected over what period of time and by what methods. It is particularly helpful to researchers in outlining some of the difficulties and pitfalls when using this data. These aspects of the data appear to have been carefully thought through in this report. The authors also provide information on how to apply to use this data for research.

I have some minor comments for improving the paper. In the abstract, it would be helpful to understand the ages of the mothers and daughters. Currently it says that the data are collected at 21 and 20 timepoints but does not describe the ages of the participants. Secondly, in the description of the G1 cohort, for example in Figure 2, it is not clear if the ages described are the exact age of the participants or are the average ages.

Are sufficient details of methods and materials provided to allow replication by others?

Yes

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Reviewer Expertise:

Women's health  Epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Wellcome Open Res. 2023 Nov 21.
Gemma Sawyer 1

We are grateful to the reviewer for their useful suggestions to improve the paper. Details of specific changes are outlined below (in italics), and we hope these address the reviewers’ critiques.  

This paper outlines the data recorded on menstrual cycle features for mothers and index daughters in the Avon Longitudinal Study of Parents and Children. The multi-generational and longitudinal nature of the data makes it valuable to researchers. The data note helpfully outlines what data has been collected over what period of time and by what methods. It is particularly helpful to researchers in outlining some of the difficulties and pitfalls when using this data. These aspects of the data appear to have been carefully thought through in this report. The authors also provide information on how to apply to use this data for research. I have some minor comments for improving the paper. In the abstract, it would be helpful to understand the ages of the mothers and daughters. Currently it says that the data are collected at 21 and 20 timepoints but does not describe the ages of the participants.

We have added information on the ages of the mothers and daughters across the timepoints in the abstract.  

Secondly, in the description of the G1 cohort, for example in Figure 2, it is not clear if the ages described are the exact age of the participants or are the average ages.

We have changed the X axis label in both Figure 1 and Figure 2 to clarify that these are the average (mean) ages of the G0 or G1 sample at each data collection timepoint.  

Is the rationale for creating the dataset(s) clearly described? Yes  

Are the protocols appropriate and is the work technically sound? Yes  

Are sufficient details of methods and materials provided to allow replication by others? Yes  

Are the datasets clearly presented in a useable and accessible format? Yes

Wellcome Open Res. 2023 Sep 19. doi: 10.21956/wellcomeopenres.21901.r66481

Reviewer response for version 1

Mandikudza Tembo 1

Abstract 

Overall, the abstract and key messages read very well. However, it would be helpful if the abstract noted where (geographical location) and when (time period including month and year) this research took place.

Introduction 

Very well written. However, please note the following edits:

  • Citation missing for the first line.

  • Citation missing for line ending with “idiopathic”.

  • The introduction could be enriched by looking at the differences in research and reporting of problematic menstrual features between LMICs and HICs. I think this should be included to provide context. Also, there something to be said about perceptions – perhaps there is underreporting because there’s a lack of understanding or education around what is considered “problematic”

Methods

  • REDCap (Research Electronic Data Capture) should appear first before being abbreviated. Also is there a citation available for this?

  • For figure 2 – how was “started period” defined? Would one day of spotting suffice? Was three sequential months of bleeding? Girls often have irregular bleeding at menarche so it would be better to understand what “started period” actually meant to those reporting.

  • The question around heavy bleeding is interesting as this is very subjective. Curious as to how this was interpreted by participants… Were they considering “heavy” in relation to their personal experiences or in comparison to their perception of what is “normal”?

  • Similar comments for pain – how is a participant interpreting this question? It may have been better to look at the effect of pain on the ability to conduct usual daily activities.

  • I commend the use of repeated measures.

  • Further considerations should also explore the effect of medications/vaccinations on the menstrual cycle. There is a growing body of literature that suggests these could inform the menstrual cycle.

Are sufficient details of methods and materials provided to allow replication by others?

Partly

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Reviewer Expertise:

menstrual health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Wellcome Open Res. 2023 Oct 7.
Gemma Sawyer 1

We thank the reviewers for their constructive and helpful comments. We have detailed our response below (in italics) and hope these address the reviewer’s critiques.

Abstract Overall, the abstract and key messages read very well. However, it would be helpful if the abstract noted where (geographical location) and when (time period including month and year) this research took place. We have updated the abstract to include this information.

The variables presented in this paper have been collected in a UK, Bristol-based cohort since 1991.  

Introduction Very well written. However, please note the following edits: Citation missing for the first line. T

he citations to support the text in the first line are in the following sentence which outlines the specific proportion ranges for each feature.  

Citation missing for line ending with “idiopathic”.

Citations have been added.  

The introduction could be enriched by looking at the differences in research and reporting of problematic menstrual features between LMICs and HICs. I think this should be included to provide context. Also, there something to be said about perceptions – perhaps there is underreporting because there’s a lack of understanding or education around what is considered “problematic”.

We have added a sentence to the first paragraph of the Introduction highlighting differences between LMICs and HICs.  

Methods REDCap (Research Electronic Data Capture) should appear first before being abbreviated. Also is there a citation available for this?

We have addressed the order of the abbreviation. The citation is included (reference 18; Harris et al. 2009).  

For figure 2 – how was “started period” defined? Would one day of spotting suffice? Was three sequential months of bleeding? Girls often have irregular bleeding at menarche so it would be better to understand what “started period” actually meant to those reporting.

We have added a footnote to this figure to make it clear to the reader that ‘started period’ was based upon responses to the question “Have you started your period yet?” asked at each timepoint. No further information was provided in these questions to clarify how much bleeding would constitute having started their period.  

The question around heavy bleeding is interesting as this is very subjective. Curious as to how this was interpreted by participants… Were they considering “heavy” in relation to their personal experiences or in comparison to their perception of what is “normal”?

We have added a few sentences to the final paragraph of the Further Considerations explaining the subjective nature of such questions and, whilst it may pose some limitations, it is also crucial to measure and understand people’s experiences of such symptoms. Subjective reporting of heavy bleeding is also used for diagnosis of heavy menstrual bleeding.  

Similar comments for pain – how is a participant interpreting this question? It may have been better to look at the effect of pain on the ability to conduct usual daily activities.

See comment above regarding heavy bleeding – we have added a few sentences to address this. Whilst a useful way of measuring and understanding menstrual pain, these measures are not available from the ALSPAC cohort.  

I commend the use of repeated measures.   Further considerations should also explore the effect of medications/vaccinations on the menstrual cycle. There is a growing body of literature that suggests these could inform the menstrual cycle.

We have added a sentence in the fourth paragraph of the Further Considerations highlighting that there are many factors we have not mentioned that are available in ALSPAC which researchers may want to consider, depending on their specific research question. We have not provided specific mention of medications/vaccinations as we do not aim to provide an exhaustive list of all such factors in this section.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    Underlying data

    ALSPAC data access is through a system of managed open access. The steps below highlight how to apply for access to the data included in this data note and all other ALSPAC data. The datasets presented in this article are linked to ALSPAC project number B4175; please quote this project number during your application. The ALSPAC variable codes highlighted in the dataset descriptions can be used to specify required variables.

    • 1. Please read the ALSPAC access policy which describes the process of accessing the data and samples in detail, and outlines the costs associated with doing so.

    • 2. You may also find it useful to browse our fully searchable research proposal database which lists all research projects that have been approved since April 2011.

    • 3. Please submit your research proposal for consideration by the ALSPAC Executive Committee. You will receive a response within 10 working days to advise you whether your proposal has been approved.

    If you have any questions about accessing data, please email alspac-data@bristol.ac.uk. The study website also contains details of all the data that is available through a fully searchable data dictionary.


    Articles from Wellcome Open Research are provided here courtesy of The Wellcome Trust

    RESOURCES